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 1 
ZUSAMMENFASSUNG 
Helicobacter pylori ist ein Gram-negatives, mikroaerophiles, spiralförmiges und mit 
Flagellen ausgerüstetes Bakterium, welches in ungefähr der Hälfte der Menschheit den 
Magen besiedelt. Während Tausenden von Jahren der Koexistenz mit dem Menschen 
hat H. pylori Fähigkeiten entwickelt dem angeborenen und dem adaptiven 
Immunsystem zu entkommen und es zu manipulieren, um dadurch in seinem Wirt zu 
bestehen. Obwohl dieses Bakterium als Pathogen, welches Gastritis, Magengeschwüre 
und letztendlich Magenkrebs verursachen kann, berüchtigt ist, konnten wir und auch 
andere vor Kurzem zeigen, dass es auch ein nutzbringendes Allergie-
Vorbeugungspotenzial besitzt. Epidemiologische Studien haben gezeigt, dass eine 
Infektion mit H. pylori vor Asthma, anderen Allergien und vor chronisch-entzündlichen 
Darmerkrankungen (CED) schützen kann. Des Weiteren, konnte unser Labor in einem 
experimentellen Mausmodell bestätigen, dass eine Infektion die Entwicklung von 
allergischem Asthma und CED vorbeugt. Interessanterweise, reichte eine Behandlung 
mit H. pylori-Extrakt, VacA oder GGT (beides H. pylori-spezifische immunregulierende 
Proteine) aus um die Entwicklung von Asthma oder CED zu verhindern und war ähnlich 
effektiv wie eine Infektion. Die schützende Wirkung ist am stärksten wenn die Mäuse 
neonatal infiziert oder behandelt werden und sie ist abhängig von H. pylori induzierten, 
supprimierenden regulatorischen T Zellen (Tregs) sowie von dendritischen Zellen (DC) 
welche durch den Transkriptionsfaktor BATF3 kontrolliert werden und IL-10 
produzieren. 
Das Ziel dieser Arbeit war es, diese Erkenntnisse in einem translationalen 
Hausstaubmilden-induzierten Asthmamodell weiter zu entwickeln und die Auswirkung 
von prä- und postnatalen H. pylori Behandlungen des Muttertiers auf die Asthma-
Prädisposition der Jungtiere zu erforschen. Zusätzlich wollte ich ermitteln ob 
Lebensmittelallergien - eine TH2-dominierte Krankheit ähnlich wie allergisches Asthma - 
durch neonatale H. pylori Behandlung verhindert oder gelindert werden können. 
Schlussendlich war es auch unser Ziel, die den potenziellen Phänotypen zugrunde 
liegenden Mechanismen zu bestimmen. 
In dieser Arbeit konnte ich anhand mehrerer experimenteller Mausmodelle aufzeigen, 
dass eine neonatale H. pylori Infektion, sowie Extrakt und VacA Behandlungen die 
Entwicklung von Lebensmittelallergien mittels eines Treg-involvierten Mechanismus 
lindern können, obschon die Effekte nicht so ausgeprägt und robust wie im Asthma-
Modell waren. Die Behandlungen führten zu einem erhöhten Vorkommen von Tregs und 
einer stärkeren Demethylierung der Treg-spezifisch demethylierten Region (TSDR) und 
dadurch zu einer stabileren Population von Tregs. Zusätzlich konnte ich zeigen, dass 
prä- und postnatale, transmaternale H. pylori Behandlungen wirksam die Entwicklung 
von allergischem Asthma in den Nachkommen verhindert. Dieser Phänotyp war 
charakterisiert durch eine niedrigere Frequenz an DCs und CD4+ T Zellen und einer 
erhöhten Häufigkeit von spezialisierten RORγt+ und CXCR3+ Treg Subpopulationen in 
der Lunge. Des Weiteren haben wir eine Veränderung der Mikrobiota und des 
epigenetischen Profils von Tregs (nämlich der TSDR Region) beobachtet. Letzteres 
deutet auf eine qualitative und/oder quantitative Veränderung der Stabilität und 
Funktionalität der Tregs hin. Die prä- und postnatale transmaternale Behandlung führte 
nicht zu einer generellen Immunsuppression, da eine Infektion mit Influenza Virus A die 
H. pylori-induzierte Immuntoleranz brach. Bemerkenswerterweise konnte ich zeigen, 
dass der transmaternal-induzierte Schutz, ohne weitere Behandlungen, auch auf die 
zweite Generation übertragen wird, was H. pylori's Fähigkeit die Allergie-Anfälligkeit 
über mehrere Generation zu beeinflussen suggeriert. 
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SUMMARY 
Helicobacter pylori is a Gram-negative, helical-shaped, flagellated and microaerophilic 
bacterium colonizing the human stomach of about 50 % of the world's population. 
During several thousand years of co-existence with humans, H. pylori has acquired 
abilities that allow it to evade and hijack both innate and adaptive branches of the 
immune system in order to persist in its host. Recently, we and others have shed light 
on the beneficial allergy-preventing potential of this bacterium, which is rather infamous 
for its pathogenic role in promoting gastritis, gastric ulcers and eventually gastric 
cancer. Epidemiological data showed the putative protective effects of H. pylori 
infection on the course of immunological diseases, including asthma, other allergic 
diseases, and inflammatory bowel disease (IBD). Moreover, we confirmed that in murine 
experimental models, H. pylori infection prevents the development of atopic asthma 
and IBD. Interestingly, tolerizing vaccination with H. pylori-extract, VacA or GGT, which 
both are immunomodulators of H. pylori, is as efficient as live infection in preventing 
asthma and IBD. The protective effects are particularly evident in mice infected or 
treated at an early age, and depend on H. pylori-mediated induction of regulatory T 
cells (Tregs) with highly suppressive activity as well as on IL-10 produced by specific 
dendritic cell (DC) subsets that are controlled by the transcription factor BATF3. 
Herein, I aimed to further develop and extend these findings by using a more robust 
and translatable house dust mite-induced murine asthma model and by investigating 
the effects of maternal pre- and postnatal H. pylori exposure and its implication on 
asthma outcome in the murine offspring. Furthermore, I sought to assess whether food 
allergy, another typical TH2-dominated disease, might as well be prevented by neonatal 
H. pylori-specific interventions. Finally, we strived to identify the underlying mechanism 
of these potential H. pylori-dependent immunomodulations. 
In this work, I further extended the protective effects to a range of experimental food 
allergy models. I could show that neonatal infection, extract and VacA treatment 
prevents, although less efficient and robust than in the asthma model, food allergy 
development through a Treg-dependent mechanism. These treatments led to a higher 
frequency of Tregs as well as to an increased demethylation of the Treg-specific 
demethylated region (TSDR) and thus, more stable and committed Tregs. Additionally, I 
was able to show that prenatal and postnatal transmaternal H. pylori-treatments 
efficiently prevent allergic asthma development in the progeny. I characterized the 
associated altered immune correlates such as a decreased frequency of DCs and bulk 
CD4+ T cells and increased frequencies of specialized RORγt+ and CXCR3+ Treg 
subsets in the lungs. Furthermore, these effects were linked to shifts in the microbiota 
composition, as well as the epigenetic signature of Tregs (i.e. the TSDR) indicating 
qualitative and/or quantitative differences in the stability and functionality of Tregs. 
Notably, transmaternal H. pylori exposure did not lead to a generalized 
immunosuppression due to the fact that acute infection with influenza A virus readily 
broke the tolerance. Most strikingly, I was able to show that the asthma-protective 
effects were propagated to the second generation without any further treatments, 
demonstrating H. pylori's ability to beneficially impact allergy susceptibility of several 
generations. 
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1 Introduction 
1.1 Allergic Diseases 
1.1.1 Allergic asthma 
1.1.1.1 Epidemiology and etiology of allergic asthma 
In recent decades the prevalence of allergic asthma has dramatically increased, 
predominantly in developed and industrialized countries. Worldwide, around 235 million 
people are affected by asthma, many of them are children1. In Switzerland, the 
prevalence increased from 2% around 25 years ago to 7-15% among children and 6-
7% in adults2. According to the WHO, 383'000 people died due to asthma in 2015, 
mostly in low or lower-middle income countries1. In the USA, annual costs caused 
directly and indirectly by asthma are estimated to be larger than 18 billion US$3. 
Epidemiological and experimental studies found that the increasing prevalence of 
asthma and also of other allergies is caused and influenced by environmental and 
lifestyle factors including diet, country of birth, exposure to antibiotics - especially early 
in life - sanitation, exposure to pets and livestock, the delivery mode, and breastfeeding, 
as well as genetic and epigenetic factors4: 
 
Genetic factors 
Numerous studies have investigated possible links between genetics and allergy, in 
particular asthma development. Family and twin studies as well as genome-wide 
association studies (GWAS) and candidate gene studies were key to identify the most 
important genetic variants associated with asthma. 
A study investigating the association of tobacco smoke exposure and the risk of early-
onset childhood asthma and adult asthma identified 12 single-nucleotide 
polymorphisms (SNPs) of which 7 were located on chromosome 17q21, suggesting a 
high importance of the region in the disease. One of these SNPs was linked to the 
expression of the gene ORMDL3, associated with transmembrane proteins in the 
endoplasmic reticulum5. However, its function in asthma development is still elusive. 
The linkage of this SNP with early-onset asthma was reproduced in different Asian and 
European cohorts6. Furthermore, severity of asthma and asthma exacerbations were 
both shown to be associated with the very same SNP underlining the relevance of the 
17q21 region for asthma risk7,8. 
The interleukin-33 (IL-33)/ILRL1 pathway is known to be a major player in allergic 
asthma development (see chapter 1.1.1.2 Pathogenesis) and thus, multiple variants of 
the IL33 and ILRL1 genes have been elucidated to be linked to an increased risk of 
asthma in several GWAS and candidate gene studies6,9. Recent work by Traister et al. 
has revealed an association between the gene region and asthma severity10. 
The cytokine transforming growth factor-β (TGF-β) is involved in airway remodeling in 
the lungs and has a known role in the pathophysiology of asthma. Consequently, 
several TGF-β SNPs were found to be associated with asthma severity in children and 
adults11-13. 
Genetic variations within the CH13L1 region were reported several times to be 
associated with disease and severity in asthma. CH13L1/ YKL-40 is a chitinase-like 
protein, which is more abundant in serum of asthma patients undergoing airway 
remodeling, and its levels correlate with asthma severity. Chitin is a major component of 
many allergens, such as house dust mites. Thus, our body produces chitinases, which 
degrade these foreign components. Chitinase-like proteins, which bind chitin but are 
unable to degrade it, are therefore associated with allergic asthma14. In a GWAS a 
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certain CH13L1 promoter SNP was found to be linked to increased YKL-40 serum 
levels, asthma, bronchial hyperresponsiveness and decline in lung function in a Hutterite 
population of European descent and was as well predictive for asthma development 
during the first 5 years of life in another birth cohort study15. 
Furthermore, SNPs near the TLR-2 co-receptor genes TLR1, TLR6 and TLR10 were 
also shown to be associated with asthma16. 
Numerous other genetic associations with asthma have been identified, such as the 
IL9, the IL5/IL13 region or more recently a locus at position 16q126,17. Generally, the 
comprehensive genetic heterogeneity of asthma, the lack of studies in diverse ethnical 
populations, the lack of functional knowledge about newly identified genes or gene 
regions as well as gene-environment interactions are limiting the conclusions that can 
be drawn from this plethora of genetic association studies. 
 
Environmental and lifestyle factors 
The increase in prevalence of asthma and allergic diseases in general, has arrived too 
quickly to be accounted for by genetic alterations alone, and is more likely a 
combination of the latter with environmental factors, which are believed to act 
epigenetically. 
 
Modern culture-independent techniques have provided a comprehensive picture of the 
gut microbiota, its diversity and alterations due to environmental influences4,18. They are 
based on the amplification and sequencing of parts of the 16S rRNA gene; alternatively, 
metagenome or metatranscriptome sequencing is applied to obtain a higher resolution 
overview of the microbiota and to allow the detection of archaea, fungi, and viruses in 
addition to bacteria. Other emerging methods are metaproteomic and metabolomic 
analyses, aiming to characterize the functionality of the microbiome19,20. Through 
application of these modern culture-independent as well as culture-dependent 
methods, it has become increasingly clear that the composition of the gut microbiota is 
strongly influenced by environmental and lifestyle factors, which in turn affect the risk of 
allergic and other non-communicable diseases (NCDs). Better personal hygiene, smaller 
family size, dietary changes, and the excessive use of antibiotics in industrialized 
countries have all been held responsible for changes in the gut microbiota and allergy 
risk21-23. Several studies have reported beneficial effects on allergic outcomes of 
growing up in rural farming environments; livestock exposure, and therefore, early or 
prenatal microbial exposure appears to account for the lower allergy risk of farmers' 
children24,25, which has been attributed mechanistically to differences in innate immune 
responses, as well as increased number and functions of cord blood regulatory T 
cells26,27. Moreover, bacterial communities in dust samples isolated from households 
with dogs or cats were found to be richer and more diverse, and exposure to such 
environments during infancy is known to protect against allergic disease development in 
childhood4,28,29. 
A reduced gastrointestinal (GI) tract microbiota diversity is clearly linked to early-onset 
NCDs, including atopy30, eczema31-34, and asthma35. The reduced GI microbiota 
diversity in allergic children is dominated by Firmicutes36-38, and members of the 
Bacteroidaceae family39 and more specifically, by increased numbers of Bacteroides 
fragilis40,41, Escherichia coli, Clostridium difficile34,42,43, Bifidobacterium catenulatum36-38,44, 
and Bifidobacterium longum45-47, and a lower prevalence of Bifidobacterium 
adolescentis, Bifidobacterium bifidum, and Lactobacillus species45-48. These general 
trends are not confirmed by all studies; for instance, a study in Norway found a lower 
rather than higher concentration of E. coli among allergic individuals45. Also, in a study 
by Verhulst et al.49, children who developed wheezing had a lower prevalence of C. 
difficile. The reduced exposure of Western populations to microbes that are not 
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classically categorized as constituents of the commensal microbiota, such as the 
gastric colonizer and pathobiont Helicobacter pylori50-52, or intestinal helminths53,54, also 
increases the risk of allergic diseases4. 
Lifestyle factors such as delivery mode and breast-feeding strongly affect the 
establishment of the human gut microbiota and the risk of allergic outcomes. The 
recent finding that bacterial DNA is present in the newborn's first stool and in the 
fetoplacental unit suggests that the acquisition of the intestinal microbiota may already 
begin in utero and is then further shaped during birth and postnatally55-57. At birth, first 
major microbial exposures originate from the maternal vaginal and perianal microbiota. 
Consequently, the intestinal microbiota of newborns resembles that of his or her 
mother's vagina58. In contrast, neonates delivered by means of cesarean section (CS) 
acquire a gut microbiota that is similar to the one found on maternal skin. This is then 
followed by the typically slower (compared to vaginally delivered infants) acquisition of a 
more complex microbiota59,60. Infants born by means of CS are at higher risk for 
respiratory distress61, asthma62 and atopy, as well as obesity63, and type I diabetes64. 
Furthermore, CS involves antibiotic exposure and can delay the onset of breastfeeding, 
which negatively influence the establishment of a normal healthy gut microbiota31,65,66. 
Indeed, breastfed (>4 months) neonates exhibited a reduced risk of developing asthma 
until 8 years of age67. Evidence is available that breastfeeding protects against atopic 
dermatitis, wheeze in early childhood and cow's milk allergy68. However, the data are 
inconsistent, as other studies have reported no benefit of breastfeeding in children from 
non-atopic families or in decreasing the risk of asthma in infants at 5 years of age69,70. 
Overall, the aforementioned studies imply that early-life or even prenatal exposure to 
microbes is critical for shaping a healthy GI tract microbiota, which can lower asthma 
and general allergy risk later in life4. 
More recently, the characterization of the airway microbiome has demonstrated that not 
only the GI tract microbes, but also the lung and airway microbiota exhibits great 
differences between asthmatics, non-asthmatics and those at risk for asthma71. A 
reduced microbiota diversity with an increased prevalence for Proteobacteria species 
was reported in patients with asthma72. Moreover, corticosteroid treatment-responsive 
patients differ in microbial lung composition from their corticosteroid-resistant 
counterparts73. 
Not only bacterial colonization but also viral respiratory infection early in life strongly 
influences the risk for allergy, in particular asthma development later in life. Infant 
respiratory tract infections by Respiratory syncytial virus (RSV) and human rhinovirus 
(HRV) are associated with a significantly higher risk for asthma development later in life 
as shown is various studies74-79. 
 
Another environmental determinant for allergy risk is the exposure to indoor allergens 
from mainly house dust mites (HDM), furred pets, mice, cockroaches or fungi. Already 
in 1990, Sporik and colleagues could demonstrate that children highly exposed to HDM 
during their first year of life have an elevated risk for allergic sensitization and asthma if 
followed to the age of 11 years80. Subsequent studies have further underlined the 
positive correlation of HDM sensitization early in life and later development of allergic 
rhinitis, persistent wheeze and asthma81-84. Lately, Baiz et al. and Richgels et al. could 
show that already prenatal or very early HDM exposure via the placenta or breast milk 
might potentiate the risk for allergic respiratory diseases85,86. In addition to HDM, a great 
body of literature could demonstrate that early-life exposure to cockroaches and mouse 
allergens is highly associated with allergic disease prevalence and severity, especially in 
urban areas87. In one compelling inner-city birth cohort study by Donohue et al., it was 
even shown that mouse and cockroach sensitization increases the prevalence for 
atopic dermatitis, allergic rhinitis and asthma in an allergen-specific IgE dose-dependent 
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manner88. On the opposite of these aforementioned clear trends, numerous 
contradictory studies and systematic reviews about the association of furred pets and 
allergy risk exist. In summary, there is probably no increased risk associated with having 
pets, in one study rather a diminished risk for asthma after cat allergen exposure was 
reported87. Recently, Wegienka et al. focused on subgroup analyses (race, gender and 
delivery mode) and found different associations dependent on the subgroup. Thus, the 
great variability of earlier studies might be explained by the lack of subgroup division89. 
Similar to pet allergens, fungal allergens are ubiquitous in the environment and studies 
reporting both positive and negative correlation of fungi exposure and allergy 
development have been published. Visible fungal exposure such as in mold-damaged 
homes have been linked to an increased risk of allergic rhinitis and asthma90. These 
findings are accentuated by quantitative DNA-based91 and β-1,3-glucan 
measurements, the latter showing that exposure to low levels of fungal dust is 
predictive for asthma in contrast to greater levels which are protective92. However, not 
the concentration alone, rather the fungal diversity might be the reason for the 
protective effect as recently shown by Tischer et al.93.  
 
Beyond the above-mentioned environmental components, air pollution such as traffic-
related air pollution (TRAP) and environmental tobacco smoke (ETS) is another 
important factor shaping the prevalence of atopic diseases, in particular asthma. 
Worldwide, a plethora of studies could demonstrate how TRAP negatively affects lung 
development and consequently, potentiates the development of asthma and chronic 
obstructive pulmonary disease94-96. In particular, prenatal exposure (second trimester) to 
benzene and nitrogen dioxide was linked to an elevated risk for clinically significant low 
lung function, demonstrating the dramatic effects of air pollution on fetal lung 
development97. Moreover, in another study prenatal particulate matter and black carbon 
exposure increased the risk for wheezing by age 2 years98, in addition to a study which 
found that prenatal particulate air exposure was significantly associated with asthma at 
age 6 years99. Furthermore, early-life postnatal TRAP-exposure is also impacting 
asthma development. A recent study by Gehring and colleagues applied meta-analyses 
and pooled analyses on four birth cohort studies including 14126 participants from 
Germany, Sweden and the Netherlands and found that exposure to pollutants early in 
life contributes to the development of asthma throughout childhood and 
adolescence100. 
However, in terms of air pollution, the strongest and most consistent pre- and 
postnatally-induced allergic sensitization101 and asthma102-promoting effects emerge 
from ETS. Pooled analyses from 15 European birth cohorts demonstrated that even 
exposure of the mother (non-smoking) to only second hand smoke during the 
pregnancy will lead to an increased risk for wheezing at age 2 years, which is further 
increased by postnatal second hand smoke exposure and further elevated in children of 
atopic families103. Most strikingly, Li et al. could show that not only maternal but also 
grandmaternal smoking during the mother's fetal period may increase the risk for 
childhood asthma in the F2 offspring104. 
1.1.1.2 Pathogenesis of allergic asthma 
Asthma is a chronic inflammatory disorder that affects the conducting airways leading 
to reversible airflow limitation, bronchial hyperresponsiveness, mucus overproduction, 
airway wall remodeling and/or narrowing. Patients suffer from recurrent shortness of 
breath, wheezing, coughing and chest tightness. Two types of asthma, allergic and 
non-allergic (intrinsic) asthma have been defined. The majority of asthmatic children and 
approximately 50% of asthmatic adults have the allergic type of asthma. Allergic 
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asthma is indicated by serum immunoglobulin E (IgE) antibodies and/or a positive skin 
prick test against inhaled allergens, most commonly HDM, but also animal dander, 
fungal spores, plant or tree pollen or peanuts. Intrinsic, non-allergic asthma does not 
involve the adaptive immune system, such as T helper 2 cells (TH2 cells) and is not 
associated with allergen-specific serum IgE levels and usually develops later in life3. 
Recently, clinicians have realized that due to the diversity of the phenotypes, a more 
precise classification into several sub-endotypes of asthma might be superior to the 
above-mentioned rough division105,106. It is now acknowledged that the traditional 
definition of asthma rather embraces a collection of diseases or a syndrome and not a 
single disorder107. Recently, Wu and colleagues, found 6 different types of asthma using 
an unsupervised phenotyping approach108. Nevertheless, for the sake of brevity and 
relevance for this thesis, only the pathogenesis including the molecular and cellular 
basic immunology of the most common disease-collective called TH2-driven or TH2-high 
eosinophilic asthma will be described in the following sections. 
 
Type 1 to 4 immune responses 
Type 1, type 2 and type 3 (also called type 17) immune responses are characterized by 
their major cellular representatives T helper 1 cells (TH1), T helper 2 cells (TH2) and T 
helper 17 cells (TH17), which are all subpopulations of CD4+ T cells. However, also their 
innate counterparts, the innate lymphoid cells (ILCs) and other cell types play a major 
role within the three types of immunity: 
Type 1 responses are initiated by IL-12 secretion of dendritic cells (DCs) and 
macrophages preceding the activation of natural killer cells (NK) and group 1 ILCs 
(ILC1s). Subsequently, TH1 cells are activated and produce IL-2, interferon-γ (IFN-γ) and 
lymphotoxin-α and thus together with ILC1s and cytotoxic CD8+ T cells promote type 1 
immunity, characterized by intense phagocytic activity, mainly directed against 
intracellular threats, such as viruses, some bacteria and tumors. TH1 and ILC1s are 
induced by the master regulator transcription factor T-bet, which drives the expression 
of other type 1-specific transcription factors and effector cytokines but also suppresses 
the ones from other lineages, therefore functioning as a lineage determinant109,110. 
Type 3 immunity is launched by the production of IL-1β and IL-23 by DCs and 
macrophages, which thereafter activates ILC3s and TH17 cells driven by the master 
regulator transcription factor retinoic acid receptor-related orphan receptor-γt (ROR-γt). 
The subsequent effector phase is dominated by IL-22 and IL-17 secreted by lymphoid 
cells, antimicrobial peptides produced by epithelial cells and infiltration by neutrophils. 
Type 3 responses are directed at extracellular microorganisms, like most bacteria and 
fungi109. 
Moreover, a mixed type 1 and 3 response with lymphoid cells producing both, IFN-γ 
and IL-17 might occur in case of extensive tissue injury and strong inflammation111,112. 
Type 2 responses apply tissue repair mechanisms to fight against large extracellular 
organisms such as helminths113. For instance, mucus secretion and collagen deposition 
is induced at mucosal sites by type 2 responses. In this type of immunity epithelial cell-
derived IL-25, IL-33 and thymic stromal lymphopoietin (TSLP) production precedes the 
recruitment of ILC2s, eosinophils and later TH2 cells accompanied by IgG1+ and IgE+ B 
cells and IL-4, IL-5 and IL-13 up-regulation109,114. As described for type 1 and type 3, 
type 2 responses are induced and maintained as well by a specific master regulator 
transcription factor: GATA-3 induces and drives the ILC2 and TH2 cell lineages and 
simultaneously inhibits both type 1 and type 3 responses115. 
A type 4 immune response that prevents microorganisms and parasites from reaching 
deeper tissue sites, has also been proposed. It functions by releasing large amounts of 
INTRODUCTION 
 
 8 
IgA into the intestinal lumen, tears, saliva, sweat and also the respiratory epithelium, all 
sites with a high bacterial or parasitic burden. IgA is the most abundantly produced 
antibody isotype in mammals, mainly functions through interactions with multiple 
receptors and blocks the microorgansims before they reach the vulnerable tissue site 
where they potentially would induce a type 1 or 3 response116. Other constituents of the 
type 4 immunity are antimicrobial peptides secreted by epithelial cells and the 
production of mucus109. 
In summary and according to Gérard Eberl's equilibrium model of immunity, all four 
above-mentioned arms of immunity rely on a dynamic equilibrium, well balanced in the 
healthy state. The four types of responses compete with each other and are in a 
mutually inhibitory state. Dysregulation of the equilibrium leads to pathological 
inflammation. Dysregulated type 1 responses are involved in systemic lupus 
erythematosus and type 1 diabetes. Malfunction of type 2 immunity drives allergic and 
pro-fibrotic pathologies, whereas type 3 responses are responsible for autoimmune 
inflammatory diseases, such as inflammatory bowel disease, rheumatoid arthritis and 
multiple sclerosis109. 
 
Regulatory T cells 
Regulatory T cells (Tregs) were initially described in mice as an autoimmunity-
suppressing CD4+ T cell population, which expresses the IL-2 receptor α chain, 
CD25117,118. Later, Hori as well as Fontenot et al. found that Treg development is 
controlled by the transcription factor forkhead box P3 (FoxP3), which was thereafter 
soon established as the main marker for Tregs119,120. Tregs drive tolerance to self-
antigens, commensal microbiota and environmental antigens, such as allergens121,122. 
Two major Treg populations exist: The thymus-derived or natural Tregs (tTregs or 
nTregs), which mainly control tolerance to self-antigens and the in the periphery from 
conventional or naive CD4+ T cells derived, induced or peripheral Tregs (iTregs or 
pTregs), which mainly mediate tolerance to microbes and allergens. The generation of 
iTregs at mucosal sites requires high levels of TGF-β and retinoic acid (derived from 
Vitamin A), both secreted by C103+CD11c+ DCs in the intestine or by tissue resident 
macrophages in the lung123,124. Neuropilin-1 (Nrp-1) and Helios are both expressed by 
nTregs but not by iTregs and are therefore often used as markers to differentiate the 
two subsets125,126. nTregs and iTregs harbor distinct T cell receptor (TCR) repertoires; 
nTregs are rather directed against self-antigens whereas iTreg-T cell receptors are 
biased toward nonself antigens127,128. iTregs are also reported to be less stable than 
nTregs and can lose FoxP3 expression and consequently their lineage specific 
expression profile129. Induction and stability of FoxP3 expression and therefore of the 
Treg lineage is controlled by multiple signaling pathways (Figure 1) and epigenetically 
regulated mechanisms. TCR signaling via the nuclear factor of activated T cells (NFAT) 
and activator protein 1 (AP1), but also via the transcription factors cAMP-responsive-
element-binding protein (CREB), activating transcription factor (ATF) and SP1 was 
reported to activate FoxP3 expression. Also co-stimulation, in the case of nTregs via 
CD28, is required for the induction of FoxP3 expression. In the periphery CD28 
stimulation rather prevents iTreg differentiation. Moreover, cytokine signals triggered by 
receptors harboring the common cytokine-receptor γ-chain, which transmits IL-2 and 
other cytokine-mediated signals, are crucial for FoxP3 expression. Additionally, TGF-β-
signaling via the TGF-β-receptor plays a pivotal role in Treg induction and maintenance, 
predominantly in iTregs in the periphery130. The contribution of each of these pathways 
may differ between Treg subsets and the exact molecular mechanism and the timing of 
the interplay still needs to be elucidated. 
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Figure 1: Multiple signaling pathways converge to regulate FoxP3 expression. TCR 
firing, co-stimulation via CD28, cyotokine-mediated signaling via the common cytokine-receptor 
γ-chain and the TGF-β-receptor all converge to induce and maintain FoxP3 expression via the 
trancription factors cAMP-responsive-element-binding protein (CREB), activating transcription 
factor (ATF), SP1, nuclear factor of activated T cells (NFAT), activator protein 1 (AP1), TGFβ -
inducible early gene 1 (TIEG1), mothers against decapentaplegic homologue 3 (SMAD3) and 
signal transducer and activator of transcription 5 (STAT5). Adapted from 130. 
 
Furthermore, FoxP3 expression and thus, Treg lineage stability is controlled by a region 
called Treg-specific demethylated region (TSDR, or also named conserved noncoding 
sequence 2, CNS2) containing many CpG motifs. This locus is highly demethylated in 
stable Tregs assuring FoxP3 expression stability and inheritance. iTregs exhibit a less 
hypomethylated TSDR than nTregs and are therefore less stable129,131,132. Other highly 
conserved non-coding regions that are influenced by epigenetic alterations are the 
Foxp3 promoter and a TGF-β-sensor element. The Foxp3 promoter contains CpG 
motifs, which are fully demethylated in Tregs compared to weakly methylated in 
conventional T cells. Additionally, acetylation of histones at the promoter region as well 
as within the TGF-β-sensor element is increased in Tregs relative to other T cells130.  
The immunosuppressive function of Tregs is mediated by secreted inhibitory cytokines 
(IL-10, TGF-β, IL-35) and cytolytic molecules (granzymes A and B). Additionally, 
deactivation of antigen presenting cells (APCs) by means of cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4) and lymphocyte activation gene 3 (LAG-3), deprivation of 
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IL-2 through CD25 as well as tuning of metabolic pathways through CD73 and CD39 
are also mediators of Treg function122. 
Recently, it became apparent that Treg cells are able to further differentiate into specific 
effector subsets similar to conventional T cells. Evidence for TH1-like (expressing Tbet 
and IFN-γ), TH2-like (expressing GATA3 and interferon regulatory factor-4, IRF4) and 
TH17-like (expressing ROR-γt and IL-17) Tregs was reported in several studies133,134. In 
summary, Tregs are a very heterogeneous cell population with a high level of plasticity. 
Depending on whether the cytokine environment is biased towards a type 1, type 2 or 
type 3 immune response, they are able to adapt and partially differentiate into these 
subtypes, which allows them to migrate to effector sites and dampen the associated T 
helper cell activity109. 
 
TH2-high eosinophilic asthma 
In children, TH2-driven asthma is initiated by allergic sensitization caused by 
environmental factors, such as viral respiratory tract infections, exposure to oxidants like 
cigarette smoke or other airborne pollutants (discussed in the previous chapter) often 
accompanied by eczema. This activates airway epithelial cells to produce for example 
IL-25, IL-33 or TSLP135. Frequent subsequent development of allergic rhinitis can then 
progress to asthma in children who are susceptible due to a genetic predisposition or 
other less well-understood factors. This sequence of increasing symptoms is termed 
the atopic march3 and leads to induction of a type 2 inflammatory cascade (Figure 2). 
During sensitization, lung conventional DCs (cDCs) and epithelial cells can be directly 
activated by allergens. CCL2 and CCL20 are chemokines that are produced by 
epithelial cells in the lung upon exposure to allergens and that recruit immature pre-
cDCs from the circulation3. IL-25, IL-33, TSLP, GM-CSF and/or IL-1α, but also danger 
signals like uric acid or ATP can also be released from activated epithelial cells, which 
favors the maturation of CD11b+ cDCs, in contrast to CD103+ cDCs that would induce 
tolerance to inhaled allergens. These CD11b+ cDCs are dependent on the transcription 
factor IRF4 for maturation and migration to the draining lymph node3. Subsequent 
expression of co-stimulatory molecules such as the OX40 ligand further initiates 
migration of the CD11b+ cDC to the draining lymph node (Figure 2)135. Upon arrival, the 
DC activates naive CD4+ T cells via the interaction of its OX40 ligand with OX40 on the 
T cell and via other co-stimulatory interactions. The resulting IL-4 competent T cells 
migrate to B cell zones where they differentiate into T follicular helper (TFH) cells prone to 
induce B cells to undergo IgE class-switching which leads to the production of allergen-
specific IgE antibodies by differentiated plasma B cells (Figure 2)135. Other IL-4 
competent T cells proceed into the circulation where they maturate into TH2 cells. 
Subsequently, these TH2 cells migrate to the airway epithelium and the subepithelial 
mucosa where they produce IL-5 and IL-13 in large quantities, inciting inflammatory 
and remodeling changes in the airways by recruiting and sustaining eosinophils, mast 
cells, basophils and goblet cells135,136. However, also IL-33 from epithelial cells is able to 
activate mast cells and basophils to secrete vasoactive amines, lipid mediators, 
chemokines, and cytokines like IL-4136. IL-33 is also able to recruit and activate ILC2 
cells (Figure 2), which secrete more IL-5 and IL-13 and act in a similar way as TH2 
cells3,135. IL-5 is the key cytokine driving eosinophilia, recruiting eosinophils from the 
bone marrow, whereas IL-13 mediates the induction of chemokines, a pro-fibrogenic 
stromal environment, alternative macrophage activation, smooth muscle alternations 
enhancing airway hyper-responsiveness and goblet cell metaplasia which leads to an 
excess of pathological intraluminal mucus (Figure 2)135,136. Furthermore, IL-13 primes the 
vessel wall for upregulation of the adhesion molecules VCAM-1 and ICAM-1, facilitating 
eosinophil exit3. Due to a shared receptor type, IL-4 supports and contributes to the 
same effects as IL-13136. Massive infiltration of eosinophils causes airway wall 
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remodeling and subepithelial membrane thickening via the secretion of TGF-β3. The 
eosinophil-derived eosinophil peroxidase induces bronchial hyperreactivity and triggers 
adaptive immunity via effects on DCs. Moreover, activated cytolysed eosinophils are 
able to release extracellular DNA traps containing eosinophilic granules3. This might lead 
to high local concentrations of eosinophilic tissue-damaging agents like eosinophil-
derived neurotoxin, eosinophil peroxidase and major basic protein3. Steadily increasing 
occupation of the high-affinity IgE Fc immunoglobulin receptor FcεRI on mast cells and 
basophils by allergen-specific IgE enhances the survival of these cells and provides a 
rapid mechanism for cell activation by antibody crosslinking upon further allergen 
exposure. Allergen-mediated FcεRI activation leads to the immediate production and 
release of vasoactive amines and lipid mediators that cause acute decrease of 
respiratory function, while also initiating the delayed phase by recruiting more 
inflammatory cells136. 
Overall the following pathological changes are induced: Epithelial goblet cell metaplasia, 
hyperplasia and excess of epithelial mucin stores, subepithelial fibrosis with increased 
deposition of collagen I/III and V as well as fibronectin and tenascin C, increased gland 
volume, changes in smooth muscle cells causing hypertrophy and hyperplasia, 
increased number of blood vessels. This results in the following clinical symptoms: 
Shortness of breath, wheeze, cough and sputum production. Exacerbations vary from 
mild to severe and in the worst case can result in fatal respiratory failure135. 
 
 
Figure 2: Type 2 pathogenesis of asthma. Epithelial-derived TSLP, IL-25 and IL-33 activates 
mast cells, basophils and ILC2s, in addition to DCs that migrate to the draining lymph node 
where they induce TH2 and TFH cell differentiation from naive CD4+ T cells. TFH cells induce B cell 
IgE class-switching in B cell zones which further leads to plasma cells producing allergen-
specific IgE. TH2 and ILC2 cells are recruited to the airway epithelium and the subepithelial 
mucosa and produce IL-5 and IL-13, which leads to goblet cell metaplasia and eosinophilia, 
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inducing pathological changes predisposing an individual to asthma and to asthma 
exacerbations. TSLPR, TSLP receptor; OX40L, OX40 ligand. Adapted from 135. 
 
The persistence of type 2 immune responses initiated in childhood is quite common 
and its occurrence is not well understood. Most likely the involved immune cells 
become primed for a TH2-dominance due to stable epigenetic changes. It is known that 
in the neonatal window the immune system is more susceptible for such sustainable 
changes that might last for an entire life or even be transferred to the next 
generation137,138. 
1.1.1.3 Treatment of allergic asthma 
Both inhaled β2-adrenergic receptor agonists and glucocorticoids (approved in 1969 
and 1974) have long been the main treatment for people suffering from asthma. 
Nevertheless, leukotriene receptor antagonists and IgE-directed (e.g. omalizumab, 
monoclonal antibody specific for IgE, by Roche/Genetech and Novartis) therapies were 
launched in recent years139. Other novel therapies, in clinical trial phase II and beyond, 
are IL-5, IL-13 and TSLP inhibitors. Mepolizumab is a humanized monoclonal antibody 
by GlaxoKlineSmith that binds and prevents IL-5 from interacting with the α-chain of the 
IL-5 receptor. It was shown to be effective only in a subgroup of asthma patients with 
persistent eosinophilia. Benralizumab by MedImmune/AstraZeneca is a humanized 
antibody that directly binds and blocks the α-chain of the IL-5 receptor. Reslizumab 
from Teva Pharmaceutical Industries is another humanized monoclonal antibody 
specific for IL-5. Benralizumab and reslizumab were also shown to be specifically 
effective in patients with persistent eosinophilia despite corticosteroid treatment. 
Lebrikizumab (Genetech/Roche) is an antibody that completed several phase II and III 
studies more or less successfully; it blocks IL-13 from binding to IL-4Rα and therefore 
prevents the formation of the IL-13-IL-13Rα1-IL-4Rα complex, which together with IL-
13Rα2 would form the IL-13 receptor. GSK679586 from GlaxoSmithKline prevents 
binding of IL-13 to IL-13Rα1 and Tralokinumab from MedImmune/AstraZeneca 
prevents binding to IL-13Rα2, whereas Dupilumab (Regeneron Pharmaceuticals) blocks 
both, IL-4 and IL-13 signaling by blocking IL-4Rα. All these IL-13/IL-4 targeting 
medications were reported to be particulary effective in patients with evidence for type 
2 inflammation135. Furthermore, Amgen has a TSLP inhibitor in the pipeline (AMG 157) 
that recently completed phase I and phase II trials. It is a fully human antibody that 
blocks the interaction of TSLP with its receptor and has already been shown to 
attenuate early- and late-phase responses to allergens135,140. 
At the moment patients suffering from very severe asthma are subjected to a 
combination of long-acting β2-adrenergic receptor agonists, inhaled and oral 
corticosteroids, leukotriene receptor antagonist, long-acting anticholinergic medication 
and IgE-directed therapies. Generally, the guidelines assume a positive correlation of 
the severity of asthma and the strength of the type 2 response because it is 
recommended to increase the dose of corticosteroids and add IgE-targeted 
medications in case of disease worsening139. However, such a relationship might not be 
true for all patients due to the existence of large subgroups that do not exhibit 
eosinophilia and therefore might not react to type 2-targeted therapies141. 
Another treatment method that is more and more frequently used, is allergen 
immunotherapy (AIT) for which steadily increasing doses of a specific allergen are 
applied subcutaneously or sublingually to achieve tolerance in the patient. AIT was 
shown to reduce symptoms, however, so far no consistent evidence for an 
improvement of lung function exists142. 
Overall, results from recent clinical trials and experiences from decades of 
glucocorticoid therapy have shown that asthma is a heterogeneous disease and that 
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there is a need for more personalized medical interventions including the development 
of robust biomarkers. Additionally, preventive measures such as reducing viral 
respiratory infections or reduction of exposure to antibiotics or tobacco smoke in 
infancy might drastically diminish asthma prevalence. 
1.1.1.4 Animal models of allergic asthma 
To study disease mechanisms and therapy, animal models have developed into 
indispensable tools. Various species have been employed to model human-like asthma, 
such as rats143, guinea pigs144, rabbits145, sheep146, dogs147, primates148,149 and mice150. 
However, the most abundantly used standard asthma models are in mice and will be 
discussed in the following sections. 
 
Ovalbumin mouse models 
Ovalbumin (OVA) from egg white is still the most frequently used allergen in mouse 
asthma models151. Often, BALB/c or C57BL/6 mice are used. The general OVA model 
involves peripheral sensitizations followed by local challenges in the airways. The 
sensitization usually is given via the peritoneal, subcutaneous or dermal route, 
consisting of adjuvanted OVA152. Most commonly aluminum hydroxide is used as an 
adjuvant to stimulate the immune system to undergo an allergen-specific type 2 
polarization153. Other less common adjuvants are endotoxins, ozone, exogenous 
proteases, diesel exhaust and cigarette smoke154. Conrad et al. also described an 
adjuvant-free protocol155. Subsequent OVA challenge is carried out by intranasal or 
intratracheal injections or via OVA aerosols. Usually, two sensitizations distributed over 
two weeks, followed one week later by repetitive challenges are necessary156. This 
model, independent of the exact sensitization and challenge protocol, produces rather 
consistently a range of human asthma-like hallmarks in mice, such as airway 
hyperresponsiveness, elevated levels of IgE, airway inflammation, goblet cell hyperplasia 
and epithelial hypertrophy157. Nevertheless, the model harbors some drawbacks 
because it is not entirely reflecting the human situation, which usually involves a chronic 
inflammation of the airway wall and airway remodeling that is absent in the mouse 
model. Furthermore, it was shown that the hallmarks induced by some OVA models are 
short-lived and resolve within a few weeks after the last challenge157. Moreover, 
prolonged OVA-exposure leads to tolerance and consequently, a decreased disease 
phenotype158. Additionally, the antigen OVA is not known to be an allergen for human 
asthma, therefore, more recently, investigators started to use the more realistic house 
dust mite, grass pollen and cockroach extracts to induce asthma159. However, despite 
these concerns, the OVA mouse model allowed numerous crucial findings about 
disease pathogenesis and also essentially contributed to the development of 
therapeutic interventions160. 
 
House dust mite mouse models 
House dust mites (HDM), belong to the most common allergens worldwide affecting 
50-85% of all asthmatics in addition to the role they play in other atopic diseases like 
rhinitis, rhinoconjunctivitis and atopic dermatitis160. The HDMs, Dermatophagoides 
pteronyssinus and Dermatophagoides farinae consist of various allergenic proteins (e.g. 
proteases, immunogenic epitopes, chitin) and due to their own microbiota also harbor 
bacterial and fungal products such as lipopolysaccharide (LPS) and β-glucan that might 
play a role in influencing the immune system161-165. The most noticed and clinically 
relevant HDM allergens are Der p1 and Der p2 although elucidation of the geography of 
HDM allergens has brought to light that the major causative allergen in a population 
might differ regionally and between patients166,167. 
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In the HDM mouse model, distinguishing between sensitization and challenge is difficult 
because most models rely on the repetitive application of a standardized HDM extract 
without the use of an adjuvant. In the acute asthma model, on the first day, the HDM 
extract is usually applied intranasally or intratracheally, followed one week later by 
further repetitive applications of HDM extract via the same routes for approximately one 
week156,160. In contrast to the OVA model, prolonged administration of HDM extract 
does not lead to a tolerogenic response, instead elicited a human-like chronic type of 
asthma characterized by remodelling of the airways with increased mucous cell density 
and airway hyperreactivity, which persisted for a while after discontinuation of HDM 
exposure168. However, also the HDM model exhibits a few weaknesses, such as fewer 
mast cells in the epithelium of the airways in addition to lower IgE levels compared to 
human asthmatics in whom these features are highly elevated compared to healthy 
controls150,169. 
 
Generally, almost all mouse models induce rather short-lived type 2 inflammatory 
processes, which limits their translatability to approximately 50% of the patients, while 
the other half of asthmatics is suffering from a type 2-unrelated or mixed immune 
response160. Consequently, there is a need for a more diverse range of animal models 
reflecting the diversity of human asthma endotypes and their chronicity. 
1.1.2 Food allergy 
1.1.2.1 Epidemiology and etiology of food allergy 
The exact determination of the prevalence of food allergy is challenging due to 
diagnostic difficulties. Often, studies rely on self-reported diagnosis, which might be 
affected by an increased public awareness or on serology tests, which are also known 
to be unreliable170. For instance, 25% of the US population reports that they suffer from 
food allergy and 40-60% of parents believe that food causes allergy in their children171. 
However, few studies applied an oral food challenge as a more reliable diagnostic 
measure and taken together found a prevalence of food allergy of approximately 5% in 
adults and 8% in children172-174. Similar but slightly lower numbers, 1-3% in adults and 
3-8% in infants, are estimated by Brandtzaeg in an extensive review about food allergy 
from 2010175. Overall most studies reported that the prevalence of food allergy is 
increasing, although again, probably the data is often biased because it is derived from 
self-report. However, several well-designed studies have supported an increase in 
prevalence of food allergy over the past few decades. Using meta-regression of 20 US-
based surveys representing around 400'000 children between 1988 and 2011, an 
increase of childhood prevalence of 1.2% points per decade was reported by Keet et 
al.176. Furthermore, a Chinese study used oral food challenge as a diagnostic tool in 
infants over 10 years and found an increase in food allergy from 3.5% to 7.7%177. These 
and other studies clearly substantiate an international increase of the prevalence of food 
allergy. 
As described in chapter 1.1.1.1 for allergic asthma, the increasing prevalence of food 
allergy is caused and influenced by environmental and lifestyle factors as well as genetic 
and epigenetic factors. Thus, to prevent redundancy only the most important factors 
differing from chapter 1.1.1.1 are discussed in the following subchapters. 
 
Genetic factors 
As in allergic asthma, genetics and therefore atopic family history is a potent risk factor. 
In a large-scale study including 5'300 1-year-old infants, Koplin et al. could 
demonstrate that having one or two immediate family members with any allergic 
disease would increase the risk for food allergy by 40% or 80% relative to children 
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without an atopic family history178. Moreover, in 2000, Sicherer et al. reported that the 
pairwise concordance for peanut allergy was 64.3% in monozygotic twins compared to 
6.8% in dizygotic twins, also suggesting a strong role for genetics179. Despite some 
studies demonstrating association of food allergy with specific gene variants, profound 
knowledge about specific gene involvement is scarce due to a lack of replication on a 
wider scale. One of the only replicated genetic susceptibility loci for food allergy is the 
filaggrin gene, implicating the skin as a potential route of sensitization due to its role in 
barrier function. Filaggrin mutations have been repetitively associated with peanut 
allergy180,181 but also self-reported allergy to eggs, milk wheat and fish in a Danish 
population study182. Another rather well studied genetic implication are certain 
polymorphisms in the STAT6 gene, which are linked with an increase of the age of 
tolerance development in cow's milk allergy183, general food sensitization184 and risk for 
nut allergy185. Finally, two studies found that specific variants of HLA-DRB1 and HLA-
DQB1 are a risk factor for food allergy. A large US GWAS found significant associations 
of such variants with peanut allergy but not milk or egg allergy186. Additionally, in a very 
recent study by Martino et al. these findings were confirmed in a cohort of Australian 
infants including oral food challenge as a reliable diagnostic tool for some of the 
participants187. 
 
Environmental and lifestyle factors 
In the past years, the opinion that strict allergen avoidance for infants might reduce the 
risk for food allergy development later in life has shifted to the opposite notion, that 
allergen deprivation prevents early-life tolerization to oral allergens while sensitization 
would occur via other routes such as the skin. Most recent studies188-190 support the 
latter hypothesis and putative measures are discussed below in 1.1.2.3. 
 
Another factor assessed in several food allergy studies, is the level of vitamin D. Indeed 
several studies support the hypothesis that vitamin D sufficiency or intake of vitamin D 
during pregnancy is associated with a decreased risk for food sensitization191. 
 
Factors altering or shaping the microbiome, like level of hygiene, diet, antibiotics 
consumptions or delivery mode might also influence the risk for food allergy 
development. However, a recent systematic review by Marrs et al. was unable to find 
clear evidence of a protective role for microbes in food allergy192. Nevertheless, many 
microbiome-related allergy preventive effects were observed in various studies, for 
details please refer to section 1.1.1.1. 
1.1.2.2 Pathogenesis of food allergy 
There are non-toxic and toxic adverse reactions to foods (Figure 3). The non-toxic 
reaction can be divided into two main types of reactions, the non-immune-mediated 
(food intolerance) and the immune mediated reaction, which is per definition called food 
allergy. Food allergy itself is further subdivided into IgE-mediated or non-IgE-mediated 
food allergy. According to the Gell and Coombs classification, the IgE-mediated 
reaction is a type I hypersensitivity and the non-IgE-mediated reaction might be 
considered as a type III or IV hypersensitivity due to the involvement of IgG and IgM 
immune complex reactions and delayed-type or cell-mediated reactions, respectively175. 
The most common food allergens are milk, eggs, wheat, peanuts, nuts, sesame, fish 
but also some fruits and vegetables193. For the sake of brevity and relevance for this 
thesis, the following sections will mainly focus on IgE-mediated food allergy, for which 
there is a greater knowledge and understanding of the underlying immune mechanisms. 
Nevertheless, the problem of non-IgE-mediated food allergies should not be trivialized 
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due to the fact that many people suffer from such disorders (e.g. 40-50% of cow's milk 
allergy in children is non-IgE-mediated)175. 
 
 
Figure 3: Classification of adverse reactions to foods. Adverse reactions to foods can be 
divided into toxic and non-toxic reactions, of which the latter is sub-classified into non-immune-
mediated food intolerance and immune-mediated food allergy. Food allergy can be further 
classified into IgE-mediated type I hypersensitivity and non-IgE-mediated type III or type IV 
hypersensitivity. Adapted from 175. 
 
Homeostatic anti-inflammatory defense 
The mucosal immune system consists of two major anti-inflammatory mechanisms, 
which preserve oral tolerance to innocuous food antigens (Figure 4). On the one hand, 
there is immune exclusion mediated by secretory IgA (SIgA). These secretory antibodies 
are exported by the polymeric Ig receptor (pIgR) or also called membrane secretory 
component (mSC), which is cleaved apically in the epithelium, and thereby control the 
epithelial colonization of microorganisms175. More importantly, SIgA also prevents the 
penetration of potentially dangerous agents and thereby cooperates with innate 
defenses such as the mucus layer, defensins and peristalsis. Mucosal immunity is 
stimulated by pathogens and other antigens that are taken up through epithelial 
membrane cells (M cells), but also by innocuous antigens (e.g. food proteins) or 
commensal bacteria. On the other hand, there is hyporesponsiveness avoiding 
development of local and peripheral hypersensitivity against innocuous antigens and 
microbes. This is mediated by antigen presentation (induced by the uptake of food 
antigens and microbe-associated molecular patterns; MAMPs) by CD103+ DCs and 
regulatory macrophages (see figure 4 and 5)175. Conversion of Vitamin A to retinoic acid 
by these cells leads to induction of Tregs secreting IL-10 and TGF-β and therefore 
suppressing a polarization towards TH1, TH2 or TH17 responses (see chapter 1.1.1.2, 
section: Type 1 to 4 immune responses)175. In the skin, CD11b+ DCs and Langerhans 
cells have also been reported to promote immune tolerance194. Although this adaptive 
oral tolerance is a very robust barrier in the adult considering the daily uptake of 130-
190g food protein, it is fragile during the neonatal window and maybe longer. During 
that time, build-up of a well-balanced and diverse gut microbiota together with the right 
timing and dosing of the introduction of dietary food antigens is crucial for the 
establishment of the mucosal homeostatic defense175. 
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Figure 4: Anti-inflammatory mucosal defense. Two mechanisms maintain mucosal barrier 
function: 1) SIgA (and IgM) exported by pIgR (also called mSC) control microbiota colonization 
and exert immune exclusion by inhibiting penetration of harmful agents. Particulate antigens and 
pathogens taken up by M cells stimulate mucosal immunity (graded arrows indicate degree of 
stimulation). 2) However, also innocuous soluble antigens and commensal gut microbiota 
stimulate secretion of SIgA as well as induction of suppressive responses that inhibit polarization 
towards TH1, TH2 or TH17. DTH, delayed-type hypersensitivity. Adapted from 175. 
 
Sensitization to foods and development of food allergy 
In the case of excessive antigenic influx and/or defective immunoregulation, 
hypersensitivity may be triggered and may progress to a vicious circle of 
proinflammatory cytokine production and epithelial cell apoptosis (Figure 5)175. A lot of 
research has focused on potential mechanisms that interfere with homeostatic immune 
regulation and drive this proinflammatory cycle. 
In murine models it was shown that intestinal epithelial cell-derived IL-33 promotes 
OX40L expression on intestinal DCs, which, similar as in asthma pathogenesis, leads to 
induction of TH2 cells. IL-33 has also been demonstrated to be a mediator in skin-
sensitization to food antigens (major site of sensitization in peanut and milk allergy) and 
is also increased in damaged mouse and human skin. Upon topical allergen application 
it is upregulated in keratinocytes and activates the skin-draining DCs to induce a type 2 
immune response194. ILC2s also respond to IL-33 by producing IL-4, which in turn 
suppresses the generation of Tregs in the small intestine. IL-33 also affects IgE-
mediated activation of mast cells and therefore also enhances the acute reaction to 
food in addition to its sensitizing effects. Similarly, TSLP is also able to promote food 
allergy sensitization via OX40-L expressing DCs inducing CD4+ T cells that recruit, 
through IL-3 secretion, basophils into the draining lymph nodes. IL-4 production by the 
recruited basophils promotes TH2 skewing and supports further IL-4 production by 
CD4+ T cells. TSLP is also able to directly influence basophil haematopoiesis. 
Additionally, IL-25 seems to play a similar food allergy-triggering role since it is 
upregulated in the intestine of mice with food allergy. Moreover, its transgenic 
overexpression led to enhanced experimental food allergy while lack of the IL-25 
receptor resulted in resistance against food allergy. IL-25 together with TH2 cells 
enhances the function of ILC2s, which amplify the immune response in experimental 
food allergy194. 
IL-9 has been found to be a key TH2-cytokine for the pathogenesis of food allergy in 
mouse models and humans. It is a growth factor for mast cells and is much more highly 
expressed in memory CD4+ T cells of peanut-allergic individuals compared to non-
allergic controls. Moreover, a highly IL-9-IL-13-producing mucosal mast cell population, 
induced by TH2 cells, was recently identified. These mast cells mediate the expansion of 
mature granulated mast cells in the intestine in addition to enhancing symptoms after 
oral challenge194. 
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Figure 5: Stepwise abrogation of oral tolerance in the gut. 1) Normal permeability and 
uptake of MAMPs and antigens (Ag) by regulatory DCs and macrophages (Mφs) that convert 
Vitamin A to retinoic acid (RA) which leads to the induction of IL-10- and TGF-β-secreting Tregs. 
2) Minor barrier defects of certain variables mentioned on the left, results in elevated influx of Ags 
and MAMPs. 3) If an innate or regulatory disorder exists progression into a vicious circle is 
possible leading to more increased permeability and apical receptor expression which results in 
enhanced Ag and MAMP uptake. Most probably food allergy develops between step 2 and 3 
and is reversible. 4) Further aggravation elicits epithelial overactivation, apoptosis and increased 
secretion of proinflammatory cytokines that leads to the development of apoptosis-resistant 
effector T cells, chronic inflammatory bowel disease (IBD) and tissue damage. Adapted from 175. 
 
Besides the amplification of TH2 cell responses via IL-4, IgE-activated mast cells also 
suppress Treg generation and are able to reprogram their suppressive activity to a 
rather pathogenic IL-4 secreting cell type. Reprogrammed IL-4- and IL-13-expressing 
Tregs have also been described in human subjects with milk allergy, whereas in children 
who have outgrown their food allergy an increase of Tregs producing less IL-5 
compared to allergic or healthy controls were observed194-196. 
In many food allergic individuals, the induction of the production of allergen-specific IgE 
is fundamental for the pathogenesis of the disease, however, the underlying mechanism 
and site of induction is still elusive. And despite its central role, food-specific IgE in sera 
does not always correlate with IgE-allergy due to occasional cross-reactivity with other 
allergens and the possibility of sensitization without allergy. High levels of IgE in germ-
free mice were shown to be induced in the Peyer's patches in a microbiota-dependent 
way. However, whether IgE class-switching during sensitization to foods also occurs in 
the Peyers's patches remains to be determined. Probably both, memory B cells and 
long-lived IgE+ plasma cells contribute to persistent antigen-specific IgE production 
during the course of food allergy194. 
 
Food-induced allergy and anaphylaxis 
Food allergy provokes symptoms like atopic eczema or urticaria in the skin, the mucosa 
and skin can exhibit angioedema, and in the respiratory tract, laryngedema or bronchial 
obstruction accompanied with wheezing can occur. Symptoms are also possible in the 
entire digestive tract from mouth to anus (proctitis or perianal eczema), and systemic 
anaphylaxis can be induced. However, also unspecific symptoms like vomiting, 
diarrhea, nausea and constipation are typical175. 
Basophils and mast cells secrete platelet activating factor (PAF), histamine, 
leukotrienes, inflammatory cytokines, proteases and chemotactic molecules upon 
allergen challenge and thus IgE crosslinking on their surface via the high-affinity 
receptor FcεRI. Basophils and mast cells start degranulating within a few minutes after 
IgE crosslinking, leading to an immediate allergic reaction that can be fatal due to the 
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massive release of vasoactive mediators that might lead to vascular collapse and 
anaphylactic shock197. Consequently, basophils and mast cells are key players during 
allergic symptoms and anaphylaxis in mice and humans. PAF is also produced by 
macrophages and neutrophils that constitute parts of the so-called alternative pathways 
of anaphylaxis. Basophils, macrophages and neutrophils are activated through IgG-
antigen immune complexes acting on FcγRIII and FcγRIV. There is also evidence for a 
direct allergen-induced IgE-crosslinking-dependent activation of dendritic cells and 
monocytes194. The late phase of the allergic reaction can occur several hours after 
allergen ingestion and consists of an influx of basophils and eosinophils. Even later (24-
48h) delayed-type reactions dependent on allergen-specific T cells (activated via IgE-
dependent or independent pathways) can occur197. 
1.1.2.3 Treatment of food allergy 
Up to now, strict allergen avoidance and swift administration of emergency medication 
such as antihistamines or epinephrine in case of an accidental exposure is the only 
strategy to fight food allergy since no treatment has yet been approved by the food and 
drug administration. 
However, there are some promising treatments under investigation and some of them 
are already far-advanced in clinical studies. 
Allergen immunotherapy (AIT), already mentioned in chapter 1.1.1.3, consists of the 
application of steadily increasing doses of allergen with the goal to desensitize or 
tolerize the patient against the allergen. Several routes of allergen administration have 
been tested, including subcutaneous, sublingual, oral and the epicutaneous route, 
whereas the latter two are the most promising and clinically advanced ones. Despite 
the variability of the study design and a lack of very well controlled randomized, double 
blind, placebo-controlled studies, oral immunotherapy (OIT) seems to be effective in 
desensitizing about 50% of the subjects treated for egg, milk or peanut allergy194. It was 
also shown that early-life OIT might further increase the success rate. Nevertheless, 
adverse reactions, predominantly gastrointestinal symptoms, to OIT are frequent with 
15-20% of the patients being unable to tolerate the therapy. Furthermore, patients 
tolerating OIT can have systemic reactions in association with acute infectious illness, 
exercise, or menstruation194. Sublingual immunotherapy (SLIT) and epicutaneous 
immunotherapy (EPIT), administered as drops under the tongue or as a patch directly 
on the skin, respectively, use lower doses and were, thus, shown to be safer. However, 
the increased safety comes with a decreased efficacy. Consequently, SLIT and EPIT 
studies usually determine the threshold dose of antigen tolerated rather than full 
desensitization as a measure of success and might be better suited to protect against 
accidental exposures and not to include the food into the diet. To generally increase the 
safety of AIT, recombinant allergens harboring modified epitopes, pepsin digestion or 
heat denaturalization are under investigation to reduce the risk for anaphylactic 
reactions194. 
In addition to AIT, immunomodulation has also been investigated to treat food allergy or 
to improve other treatment strategies. Supplementation of CpG motifs that act on Toll-
like receptor 9 (TLR9) in combination with AIT was shown to be effective in mice. 
Chemically modified peanut allergens or DNA vaccines as immunomodulatory agents 
are currently in clinical trials194. 
Given the clear evidence that the microbiome influences susceptibility to food allergy 
probiotics are in focus of many studies. Most recent studies have been conducted 
using strains of Lactobacilli and Bifidobacteria, and they tend to show benefits in allergy 
prevention but not in the treatment of established allergies4. Several recent trials 
however, have raised new hopes that a reduction of symptoms in adult and pediatric 
allergic rhinitis, eczema and food allergy can be achieved by the use of probiotics4. 
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Recently, a trial with peanut OIT administered together with Lactobacillus rhamnosus 
resulted in a great desensitization efficacy of 82.1% vs. 3.6% in the placebo control 
group. However, comparison to peanut OIT alone was not conducted. Moreover, oral 
fecal microbiota transplantation is currently in clinical trials194. 
IgE-inhibitors are also interesting candidates for food allergy treatment. However, most 
of these biologics are currently being tested for the treatment of asthma and not yet for 
food allergy. Omalizumab (which is already on the market for the treatment of asthma, 
see chapter 1.1.1.3) is currently being tested in combination with OIT to diminish side 
effects and treatment duration194. 
Finally, prevention rather than therapeutic treatment of existing food allergy is a crucial 
strategy to contain the increasing prevalence of this disease. It is now known that early 
oral exposure to food allergens, even in infants at risk for allergy, is preventive and 
exclusion of allergens rather leads to an increased sensitization, probably through the 
skin or airways198,199. Additionally, like for other allergic diseases, a reduced microbial 
diversity or dysbiosis are linked to an increased risk for food allergy (see chapter 
1.1.2.1), and this might be prevented by reducing misuse of antibiotics or early 
exposure to a diverse microbial environment. 
1.1.2.4 Animal models of food allergy 
Most research in the field of food allergy is conducted by using experimental mouse 
models. In contrast to the rather well established and small variety of asthma models, 
there is a broad range of distinct food allergy protocols used in literature. The most 
important differences are mouse strain, gender, age, type of allergen, allergen 
formulation, sensitization route and type of adjuvant, challenge route, time schedule and 
dosage. A comprehensive but not complete overview can be found in the review by Liu 
et al. from 2016200. 
As mentioned earlier, genetic susceptibility is an important factor for the development of 
food allergy; thus, different mouse strains react differently in the same experimental 
protocol. BALB/c mice are known to be TH2-biased and therefore are often used as a 
strain for food allergy models. However, Morafo et al. could demonstrate that BALB/c 
mice are less prone for cholera toxin (CT)-adjuvanted sensitization to peanut and milk 
allergens compared to C3H/HeJ and they also develop different immune responses 
upon challenge201. Therefore, BALB/c mice might be better suited for systemic 
sensitization and/or for mimicking allergies against other allergens. C3H/HeJ mice are 
frequently used to model peanut allergy because they are anaphylaxis-susceptible, 
probably due to a TLR4 mutation that blocks intestinal LPS signaling. However, TLR4-
deficiency in BALB/c mice was not sufficient to induce strong clinical reactions to 
peanut, demonstrating that more differences than only the TLR4 mutation contributes 
to the distinct susceptibility to food allergy of BALB/c and C3H/HeJ mice. Moreover, 
C3H/HeOuJ mice do not respond well to peanut allergy, but are a good model 
organism for β-lactoglobulin-induced allergy in contrast to C3H/HeJ mice. Despite the 
fact that C57BL/6 mice are known to be less TH2-biased, they are a useful strain to 
study mechanisms of food allergy due to the broad range of mutant strains available200. 
Mice are usually sensitized to food allergens by oral/intragastric, intraperitoneal (i.p.), or 
topical/epicutaneous application. However, also models using intradermal or 
subcutaneous injections are published. Due to the existence of oral tolerance, 
intragastric sensitization requires adjuvants such as the widely used CT or 
Staphylococcal enterotoxin B (SEB) to induce allergy. It has been suggested that CT 
enhances gut permeability, allergen uptake and TH2-biased responses, however, the 
mechanism still remains to be elucidated202,203. In contrast to CT, SEB might better 
reflect the human pathogenesis due to its association with other allergic diseases such 
as atopic dermatitis and chronic rhino sinusitis200. SEB can also induce human food 
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allergy-like blood and intestinal eosinophilia in BALB/c mice, which is not observed 
when using CT204. The mechanism of action of SEB is still elusive. 
Adjuvant-free intragastric sensitization has also been achieved for the first time by Chen 
et. al. in BALB/c mice205. 
The i.p.-route of sensitization has a high efficiency of systemically inducing allergen-
specific IgE and IgG antibodies. Often alum is used as an adjuvant increasing locally the 
concentration of allergen to stimulate macrophages206. To screen inherent allergenic 
potential of novel allergens, also non-adjuvanted i.p. injections have been used207. 
Due to growing clinical evidence for the skin as a major sensitization route for food 
allergy, several models using epicutaneous sensitization have been established. Either 
adjuvant-free epicutaneous sensitization or the additional use of tape-stripping, vitamin 
D analogs, or intradermal injections of TSLP is applied194. 
In literature only very few food allergy mouse model protocols use intranasal 
sensitization although it is known that in humans sensitization might often occur via 
food allergen dusts through the airways200,208. 
Similar to asthma models, the sensitization phase is followed by one or several 
challenges with the food antigen. Most frequently are intragastric challenges, however, 
also many i.p.-challenged models and less frequently intravenously or intranasally 
challenged models can be found in the literature200. 
In conclusion, many parameters can influence the outcome of food allergy-inducing 
protocols in mice. Research using mouse models certainly greatly improved our 
understanding of the pathogenesis and treatment of food allergy. Nevertheless, the 
enormous variability of the distinct models used in literature, makes it difficult to 
compare findings and to draw an overall picture of the mechanisms involved in the 
course of food allergy. 
1.2 Helicobacter pylori 
1.2.1 Taxonomy, prevalence and transmission 
The Gram-negative, helical-shaped, flagellated and microaerophilic bacterium 
Helicobacter pylori was first described, isolated and cultured by Marshall and Warren in 
1982. They isolated H. pylori from the stomach of a patient with gastritis209. The human 
stomach is the only known natural habitat of H. pylori although many other Helicobacter 
species inhabiting various animals are discovered every year210. 
H. pylori co-evolved with humans over 1000s of years and has perfectly adapted to the 
human gastric mucosa211. Today, roughly half of the world's population is estimated to 
be infected with H. pylori, resulting in approximately 20% of the infected individuals in 
the development of peptic or duodenal ulcers, gastric adenocarcinoma or mucosa-
associated lymphoid tissue lymphoma212,213. Consequently, the bacterium was classified 
as a pathogen and class I carcinogen by the WHO. For the remaining 80% of the 
infected individuals no clinical overt symptoms are detected214. In recent decades a 
dramatic decrease of the infection rate with H. pylori has been reported for 
industrialized and developed countries, leading to a discrepancy of the prevalence 
between developed (5-30%) and developing (50-90%) countries215,216. Hygienic 
conditions, family size, delivery mode, targeted and excessive use of antibiotics are 
some of the reasons that might explain this phenomenon217. 
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Figure 6: Electron micrographs of Helicobacter pylori. Non-dividing helical form of H. 
pylori, and an inset in the left upper corner showing a dividing bacterium. Scale bar 500 nm. 
Adapted from 218. 
 
Most individuals are infected as infants during early childhood, after acquisition H. pylori 
can persist for a lifetime in its host219. However, how the transmission occurs is still 
elusive. Gastro-oral, oral-oral and fecal-oral are the three different routes that have been 
suggested to play a role.220-222 Successful cultivation of H. pylori from gastric juice has 
been reported and thus, gastric-oral transmission might occur via this medium, most 
likely under poor hygienic conditions or during childhood223,224. Oral-oral transmission is 
a rather unlikely route of transfer since partners are often not infected with related 
strains225,226 in addition to the questionable existence of H. pylori in saliva222,227,228, 
although there is literature demonstrating traces of H. pylori in dental plaque229. In poor 
hygienic settings, fecal-oral transmission might occur due to frequent detection of H. 
pylori in human feces230-233. Additionally, transmission via water234,235 or foods236,237 is 
another possible route that has been proposed. 
1.2.2 Virulence factors 
H. pylori harbors several virulence factors mediating infection, persistence and disease 
development as well as severity. Vacuolating cytotoxin A (VacA), gamma-glutamyl 
transpeptidase (GGT), the cytotoxin-associated gene A (CagA) and outer membrane 
proteins are all known to be important virulence determinants, some of which will be 
briefly discussed in the following sections214,238. 
1.2.2.1 Vacuolating cytotoxin A 
VacA is a pore-forming toxin that is able to disrupt cell polarity, to induce vacuolization 
and apoptosis of epithelial cells as well as to modulate the immune system by affecting 
T cell proliferation and effector function239. VacA was discovered in 1988 and is present 
in slightly different forms in virtually all H. pylori strains. It is expressed by the bacterium 
as a 140 kDa protoxin which is cleaved into a 88 kDa toxin upon secretion by an 
autotransporter mechanism, which in turn is further processed into a 33 kDa (p33) and 
a 55 kDa (p55) subunit214. VacA consists of variable regions, two of which are the signal 
(s) region and the mid (m) region of the gene. The s region is typed s1 or s2 and the m 
region is typed m1 or m2240. The s1m1 combination was reported to be the most 
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virulent and cytotoxic version in contrast to the vacuolating and non-cytotoxic s1m2 or 
s2m2 versions241-245. Other more recently discovered and not well-characterized regions 
are the intermediate region (i) or the deletion region (d)246,247. 
1.2.2.2 CagA and the cag pathogenicity island 
The second important and one of the best-studied virulence factors is CagA, which was 
originally identified as a high-molecular-mass major antigen of H. pylori in patients 
infected with highly virulent strains248,249. CagA is 120-145 kDa and encoded on the cag 
pathogenicity island (cag-PAI), which is a marker for more virulent strains250. CagA is 
translocated into the eukaryotic host cell via the type IV secretion system, also encoded 
on the PAI, which is a needle-like macromolecular complex251. CagA expression, which 
is not evident in all strains, is linked to an increased risk for cancer development in the 
host, and transgenic expression of CagA in mice induced gastric carcinoma and other 
malignancies. Consequently, CagA is regarded as a bacterial oncoprotein252,253. 
Following translocation into the host cell, CagA is frequently phosphorylated on its 
tyrosine phosphorylation motifs by Src- and Abl- family kinases253. Phosphorylation 
allows the interaction of CagA with SHP-2 tyrosine phosphatase and Csk kinase while 
the unphosphorylated version is known to interact with Crk adaptor, c-Met, Grb2, 
PAR1/MARK and E-cadherin. Subsequently, these interactions result in altered cell 
signaling as well as changes in cell polarity, extrusion, motility, proliferation and pro-
inflammatory cytokine secretion253. 
1.2.2.3 Outer membrane proteins 
The outer membrane proteins HomB, BabA, IceA, SabA/B, DupA, OipA and others are 
mainly used for adherence of H. pylori to the target host cell. BabA and SabA belong to 
the best-characterized adhesins and exert their function by binding to Lewis antigens 
on the host cell surface254,255. These proteins are regarded as virulence factors as lack 
of expression renders the bacteria unable to bind to the gastric epithelial cell, thus it 
becomes non-pathogenic. BabA has probably evolved in response to distinct host 
glycosylation patterns such as the blood group of a specific region, exhibited by the fact 
that different strains around the world harbor distinct binding capacities to different 
Lewis antigens256,257. Generally, adherence of H. pylori to the gastric mucosa is 
important for initial and long-term colonization as well as for the strength of the 
inflammatory response258. 
1.2.3 Immune evasion 
H. pylori is able to persist lifelong in the gastric mucosa of the infected host despite 
inducing a rather strong immune reaction. Various strategies, evolved over 1000s of 
years of adaptation to humans, are employed by the bacterium to evade and shape the 
host's immune response in order to achieve persistence, some of which are discussed 
in the following sections. 
1.2.3.1 Manipulation of TLR recognition and signaling 
TLRs on gastric epithelial cells and immune cells should in principle be able to detect H. 
pylori pathogen-associated molecular pattern (PAMPs) like LPS, flagellin and bacterial 
nucleic acids259,260. 
However, the bacterium avoids its recognition by TLRs by a number of structural 
modifications of LPS resulting in reduced detection and biological activity, thus 
endotoxicity261-264. Furthermore, by altering the glycosylation of the O-antigen of LPS H. 
pylori generates structures mimicking human Lewis antigens and related blood group 
antigens, evading the recognition by TLRs since it is being detected as self-antigen265. It 
is still elusive which TLRs are responsible for the detection of H. pylori LPS, some 
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studies propose TLR4 as a major sensor266,267 whereas others suggest TLR2268,269 as a 
main receptor. 
Moreover, the bacterium further dampens recognition by TLRs by modifying residues 
89-96 of the N-terminal D1 domain of its flagellin, which is essential for detection by 
TLR5270,271. In addition, H. pylori, possesses a less pro-inflammatory flagellar structural 
component, which is also not released in contrast to other bacterial flagellins272. 
Besides escaping TLR recognition, H. pylori is also able to manipulate TLR signaling. 
For instance, activation of TLR2 or TLR9 signaling by H. pylori components was 
reported to induce many anti-inflammatory effects273. 
1.2.3.2 Inhibition of CLR-mediated signaling 
Another type of pattern recognition receptors, the C-type lectin receptor (CLR) is also 
able to interact with H. pylori and thus, is hijacked by it to manipulate immune 
responses. One of which is the dendritic cell-specific intercellular adhesion molecule-3-
grabbing non-integrin (DC-SIGN) expressed on DCs that can bind to bacterial ligands, 
in particular H. pylori Lex and Ley antigens which leads to suppression of TH1 cell 
development274. Moreover, DC-SIGN ligand fucose residues of H. pylori can interact 
with the signaling complex downstream of DC-SIGN inhibiting pro-inflammatory 
responses275. Recently, it was also shown that Lewis antigens of H. pylori interact with 
the macrophage inducible C-type lectin on macrophages eliciting an anti-inflammatory 
immune reaction276. 
1.2.3.3 Phagocytosis and killing by reactive oxygen species and nitric oxide 
H. pylori inhibits phagocytosis by monocytes and polymorphonuclear lymphocytes by 
using the virulence genes virB7 and virB11 and dependent on components of its type IV 
secretion system277,278. Another escape strategy by the bacterium is the α-glycosylation 
of cholesterol resulting in less phagocytosis by macrophages and dampened T cell 
activation279,280. 
Once engulfed by macrophages, H. pylori employs further strategies to survive 
phagocytosis such as delaying actin polymerization and phagosome formation and 
arresting phagosome maturation281-283. Additionally, disruption of the NADPH oxidase 
system, which produces reactive oxygen species (ROS) in polymorphonuclear cells, 
and the production of catalase and superoxide dismutase, which detoxify ROS, enables 
the bacterium to survive inside phagocytic cells284-286. In macrophages, H. pylori 
manipulates nitric oxide production, which usually kills engulfed bacteria, by employing 
its arginase to compete with the host cell's inducible nitric oxide synthase (iNOS) for the 
shared substrate L-arginine287. Moreover, H. pylori upregulates arginase II in the host 
cell, which results in reduced iNOS protein expression288. 
1.2.3.4 Inhibition of antimicrobial peptides 
Although H. pylori rapidly induces gastric epithelial cells to express antimicrobial 
peptides such as the human beta-defensin 2 (hBD2)289,290, hBD3291 and the amphipathic 
α-helical cathelicidin LL37292, hBD3 is downregulated in a CagA-dependent way during 
chronic infection293. Additionally, H. pylori exhibited resistance to hBD1 and only minimal 
susceptibility to hBD2 while hBD3 and LL37 efficiently killed H. pylori. However, the 
latter two antimicrobial peptides are only marginally detected in the human stomach294. 
In summary, efficient colonization of the gastric mucosa is achieved by the evolution of 
resistance against antimicrobial peptides as well as by manipulating the expression of 
those. 
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1.2.3.5 Interaction with and modulation of dendritic cells 
H. pylori is able to manipulate the functionality of DCs, which are highly specialized 
antigen-presenting cells that are key to bridging innate and adaptive immune responses 
by presenting and transferring captured antigens, thereby inducing various T cell 
responses. 
It was shown that phosphorylated CagA, after being taken up by DCs leads to the 
activation of SHP-2 which inhibits the serine/threonine protein kinase-1 (TBK-1) which 
in turn results in a reduced interferon regulatory factor 3 (IRF-3) translocation to the 
nucleus. Consequently, production of interferons is reduced, thus, leading to overall 
less skewing towards a TH1 phenotype295. Kaebisch et al. have also shown that in 
human DCs, CagA induces a semi-mature phenotype manifesting in low expression of 
co-stimulatory CD86, the maturation marker CD83 and IL-12p70 and elevated 
expression of the tolerogenic cytokine IL-10296. 
Despite being often regarded as a pro-inflammatory cytokine, DC-mediated IL-18 
secretion was reported to have tolerizing effects in H. pylori infection by inducing the 
differentiation of Tregs297. 
Furthermore, the virulence determinants VacA and GGT were shown to be essential for 
gastric colonization and neonatal DC-mediated tolerance in vivo298. The two factors 
probably exert their immunosuppressive function by inhibiting DC maturation via E2 
promoter-binding factor-1299 and in the case of GGT by glutamate-dependent inhibition 
of cAMP-mediated regulation of IL-6 expression300. 
1.2.3.6 Manipulation of effector T cell activity 
In addition to the indirect shaping of the T cell response via the manipulation of DCs, H. 
pylori is able to directly influence T cell activity. 
In the lamina propria, VacA is able to enter the human T cell cytoplasm by binding to β2 
integrin; upon arrival in the cytoplasm, it interferes with the TCR-IL-2 pathway thereby 
inhibiting nuclear translocation of the transcription factor NFAT, thus blocking 
expression of T-cell-response-genes301,302. Moreover, the N-terminal hydrophobic region 
of VacA is required for the formation of membrane channels, which inhibit clonal 
expansion of T lymphocytes and by reducing the mitochondrial membrane potential 
also suppress T cell proliferation303,304. And, channel-independent VacA-induced actin 
rearrangements are able to reduce T cell activation305. 
GGT is also able to directly affect T cells by blocking T cell proliferation through G1 cell 
cycle arrest306,307, depriving T cells from glutamine, reducing the expression of IL-2, 
CD25, IFN-γ and IL-17 as well as by altering the expression of the transcription factors 
c-Myc and IRF4308. 
Another mechanism of T cell manipulation is the deprivation of L-arginine required for T 
cell activation and function by H. pylori's arginase for the production of urea309. 
Additionally, cagPAI-positive strains were shown to induce the Fas ligand, thus, 
inducing apoptosis and limiting host immunity310. 
1.2.4 H. pylori and allergic diseases 
Numerous epidemiological studies have addressed, and demonstrated, an inverse 
association of H. pylori infection with asthma and other allergies with respiratory tract 
manifestations311-316. This inverse association was particularly strong in children and 
adolescents and in individuals with early onset allergies and asthma311-315. The chronic 
inflammatory skin disease atopic dermatitis/eczema has also been inversely linked to H. 
pylori infection in studies including over 3000 German school children and almost 2000 
Japanese university students317,318. Two meta-analyses have since been conducted that 
have investigated a possible inverse association of H. pylori with allergic asthma. Wang 
et al. retrieved 19 studies conducted up until 2012 (nine cross-sectional studies, seven 
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case-control studies, and three prospective cohort studies) and from these calculated a 
pooled OR for the association between asthma and H. pylori infection of 0.81319. A 
second meta-analysis -also published in 2013- which included 14 studies involving 
28,283 patients, also found a significantly lower rate of H. pylori infection in the 
asthmatics than in the controls (OR=0.84, P=0.013)316,320. Following up on the various 
observational studies in human populations, mechanistic studies in experimental 
models have examined a possible protective effect of experimental H. pylori infection in 
animal models of allergic asthma. In a murine model of allergic asthma induced by 
ovalbumin or house dust mite antigen sensitization and challenge, H. pylori infection 
confers almost complete protection against the airway hyper-responsiveness, broncho-
alveolar eosinophilia, lung inflammation and goblet cell metaplasia that are hallmarks of 
asthma in humans and mice321. These findings, amongst other discoveries of our lab 
discussed in this chapter, build the basis of my doctoral thesis. The protective effects 
are particularly pronounced in animals that have been experimentally infected during the 
neonatal period321, i.e. at an age when humans typically contract the infection from their 
mothers322. Asthma protection conferred by H. pylori is abolished by antibiotic 
eradication therapy prior to allergen challenge, and depends critically on regulatory T-
cells (Figure 7)321. The systemic depletion of Tregs abrogates asthma protection, and 
conversely, pure populations of Tregs are sufficient to transfer protection from 
neonatally infected donors to naive recipients. These results are in line with earlier 
observations that neonatal infection with H. pylori induces Treg-mediated immune 
tolerance to the bacteria323, and that mice can be actively “tolerized” against H. pylori by 
vaccination324. Interestingly, the suppressive activity of Tregs in the asthma model 
depends on interleukin-18 proficiency of the donor297, which is reminiscent of the 
prerequisites of protection against chronic intestinal inflammation. In the absence of IL-
18 signaling, neonatal tolerance to the infection cannot be established; Tregs derived 
from IL-18-/- or IL-18R-/- donors are not protective against asthma297. Previous work in 
the lab has shown that IL-18 is produced by DCs upon exposure to H. pylori 
infection297. IL-18 production by DCs appears to be required for H. pylori-specific 
tolerance. IL-18 proficiency is required both in DCs derived from bone marrow and DCs 
isolated immunomagnetically from mesenteric lymph nodes for the conversion of naive 
CD4+ T-cells into CD25+FoxP3+ Tregs297. In line with these observations, FoxP3+ Treg 
numbers in the MLNs of both infected IL-18-/- and IL-18R-/- mice are significantly lower 
than those of infected wild type mice297,316. 
Pro-IL-18 is processed by caspase-1 to yield the mature cytokine. Several recent 
publications have identified the NLRP3 inflammasome as the predominant type of 
inflammasome to become activated upon H. pylori exposure of murine DCs325-327. TLR2 
proficiency was found to be a clear prerequisite of NLRP3 inflammasome activation, as 
TLR2-/- DCs failed to activate caspase-1 and secrete caspase-1-dependent 
cytokines325. The available evidence thus points to a critical role of the 
TLR2/NLRP3/caspase-1/IL-18 axis in H. pylori-specific immune modulation, with TLR2 
signaling leading to the transcriptional activation of NLRP3, which then assembles with 
pro-caspase-1 and the adaptor protein ASC to form the functional NLRP3 
inflammasome, auto-proteolytically activate caspase-1 and process the caspase-1-
dependent cytokines IL-18 and IL-1β328. Accordingly, TLR2-deficient mice are not 
protected against allergic asthma induced by house dust mite allergens316,325. 
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Figure 7: Gastric H. pylori colonization protects against allergic asthma. Despite 
exclusively colonizing the gastric mucosa, H. pylori has robust systemic effects on T cell 
responses in other organs. The H. pylori persistence factors GGT and VacA promote chronic 
infection by tolerizing DCs and thereby promoting local Treg differentiation (lower inset). H. 
pylori-induced Tregs and DC/Treg-derived IL-10 are required for the suppression of allergen-
specific Th2 and Th17 responses in the lung (upper inset). Adapted from 316. 
 
Several H. pylori determinants have been implicated in immune tolerance, the 
differentiation and function of suppressive Tregs, and the protection against allergic 
disease manifestations. In particular, the persistence factors and H. pylori 
immunomodulators vacuolating cytotoxin (VacA) and γ-glutamyl-transpeptidase (GGT) 
are known to be required for persistent high level colonization on the one hand, and 
protection against allergic asthma on the other (Figure 7)298. VacA- or GGT-deficient 
mutants fail to colonize at wild type levels, which correlates with higher numbers of TH1 
and TH17 cells, higher expression of IFN-γ and IL-17 by restimulated mesenteric lymph 
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node (MLN) single cell preparations, and lower numbers of FoxP3+CD25+ regulatory T-
cells in MLNs298. VacA in particular appears to bias T helper cell responses towards 
Tregs, which could be attributed to VacA’s effects on DCs (Figure 7). DCs that were 
immunomagnetically purified based on their CD11c expression from the MLNs of wild-
type-infected mice induced FoxP3 and CD25 expression in co-cultured naive CD4+ T-
cells ex vivo298. This was not observed with DCs from uninfected animals or from mice 
infected with a vacA mutant298. Interestingly, both GGT and VacA can be administered 
to mice in purified form and confer a level of protection against allergen-induced asthma 
that is comparable to the live infection (see results, Engler et al. 2014). Administration of 
several doses of VacA protects efficiently against allergen-induced asthma, especially if 
the protein is provided in the neonatal tolerance window. This time frame constitutes a 
period in both mice and humans in which immune tolerance to antigens is readily 
established; therefore, it is perhaps not surprising that VacA acts most potently during 
this time. Active tolerization against allergens using VacA requires its interaction with 
DCs, as mouse strains lacking IL-10 expression in the DC compartment cannot be 
tolerized with VacA (Figure 7)316. 
Overall, these findings impressively demonstrate H. pylori's abilities to modulate the 
host immune system and to thereby positively affect the outcome of allergic diseases, 
which forms the fundament of this thesis. 
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2 Aims 
2.1 Exploitation of the immunomodulatory properties of H. 
pylori for the development of new disease prevention and 
treatment strategies 
Since our group could previously demonstrate that neonatal H. pylori infection but also 
treatment with VacA protects against OVA-induced allergic asthma in mice, we sought 
to further develop and extend these findings. Using a more robust and translatable 
HDM-induced murine asthma model, I evaluated the efficiency of the above-mentioned 
H. pylori-specific treatments by assessing typical hallmarks of asthma. Due to the fact 
that no experimental data is available about the effect of maternal pre- and postnatal H. 
pylori-specific exposure, we investigated such treatments and their implication on 
asthma outcome in the murine offspring. 
Furthermore, we hypothesized that food allergy, another typical TH2-dominated disease, 
might also be prevented by neonatal H. pylori-specific interventions. Hence, I 
established several experimental murine food allergy models and tested the effect of 
neonatal infection, and extract as well as VacA treatment on allergy prevention by 
assessing typical read-outs such as anaphylaxis score, serum levels of allergen-specific 
IgE, or mast cell protease 1 (MCPT-1) and TH2 cytokine expression of re-stimulated 
splenocytes or mesenteric lymph node-derived cells. 
2.2 Investigation of the mechanisms involved in H. pylori-
induced immune tolerance and allergy prevention 
The mechanisms involved in H. pylori-induced immune tolerance in the above-
described experimental treatment models, in particular in food allergy and transmaternal 
models, are still elusive. Thus, I aimed to identify the major molecular and cellular 
players involved by using flow cytometric analysis and transgenic mouse models. 
Moreover, my goal was to identify potential epigenetic alterations induced by the 
aforementioned interventions. Therefore, cell sorting and subsequent gene expression 
analysis by qPCR as well as bisulfit-pyrosequencing to elucidate the methylation pattern 
of known tolerogenic loci was applied. 
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3 Results 
3.1 Effective treatment of allergic airway inflammation with 
Helicobacter pylori immunomodulators requires BATF3-
dependent dendritic cells and IL-10  
 
Research article published in PNAS, 2014 
 
Authors:  Daniela B. Engler, Sebastian Reuter, Yolanda van Wijck, Sabine 
   Urban, Andreas Kyburz, Joachim Maxeiner, Helen Martin, Nir 
   Yogev, Ari Waisman, Markus Gerhard, Timothy L. Cover,  
   Christian Taube and Anne Müller 
 
Contribution:  I helped perform experiments for figures 2, 3, 4 and S4. 
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3.2 Helicobacter pylori and its secreted immunomodulator 
VacA protect against anaphylaxis in experimental models of 
food allergy 
 
Research article published in Clinical and Experimental Allergy, 2017 
 
Authors:  Andreas Kyburz, Sabine Urban, Aleksandra Altobelli, Stefan  
   Floess, Jochen Huehn, Timothy L. Cover and Anne Müller 
 
Contribution:  I contributed to the study concept and design, conducted all 
   animal experiments, performed analyses and interpretation of 
   data, and wrote parts of the manuscript. 
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3.3 Trans-maternal exposure to Helicobacter pylori induces 
stable and highly suppressive regulatory T-cells and protects 
against allergic asthma 
 
Manuscript submitted, 2017 
 
Authors:  Andreas Kyburz, Xiaozhou Zhang, Aleksandra Altobelli, Timothy 
   Borbet, Sabine Urban, Petra Paul, Christian Münz, Stefan  
   Floess, Jochen Huehn, Timothy L. Cover, Martin J. Blaser,  
   Christian Taube and Anne Müller 
 
Contribution:  I contributed to the study concept and design, conducted all 
   animal experiments, performed analyses and interpretation of 
   data, and wrote parts of the manuscript. 
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4 Discussion 
4.1 H. pylori and food allergy 
4.1.1 Epidemiological correlation 
Despite the fact that food allergy represents an important human allergic disorder of 
increasing prevalence and H. pylori is known to be inversely correlated with allergic 
diseases such as asthma, rhinitis and eczema313,319,329, studies investigating food allergy 
and its association with H. pylori infection are scarce and controversial. The existing 
studies are compromised by small sample sizes, heterogeneous populations and non-
standardized methodologies330. Corrado et al. but also others have found a positive 
correlation of H. pylori infection and food allergy, particularly for CagA-positive strains, in 
children331,332 and adults333. Other studies could not find any association334 or a negative 
association335. In this latter study a reduced production of allergy mediators (eosinophilic 
cationic protein and mast cell tryptase) in food allergy patients harboring H. pylori 
relative to non-infected patients was measured. Moreover, a reduced seroprevalence of 
H. pylori in food allergy patients was reported. Such negative associations may clearly 
be attributed to H. pylori's immunomodulatory abilities to suppress strong host immune 
responses and skew T polarization towards regulatory T cells. In contrast, positive 
associations may be explained by a breakdown of the epithelial barrier to food antigens 
due to a chronic inflammation of the H. pylori infected gastric mucosa. Here, we could 
demonstrate several preventive and protective effects for a range of H. pylori-specific 
treatments in various murine experimental models of food allergy. However, in some 
experiments, we observed elevated allergen-specific IgE and MCPT-1 levels upon 
infection but not upon extract or VacA treatment. Nevertheless, we did not find any 
other evidence for a promoting role of H. pylori in the course of food allergy. Therefore, 
our investigations rather support the studies reporting a negative association of food 
allergy with H. pylori infection. 
4.1.2 Different models leading to distinct results 
Basically no experimental data addressing the influence of H. pylori on food allergy was 
previously available. This lack might be partially attributed to the fact that no universally 
accepted food allergy model exists, which would faithfully reflect most aspects of the 
human disease. In our studies, we have applied four adapted and optimized 
complementary food allergy models, embracing different routes of sensitization and 
challenge, two common food allergens, and two different strains of mice to 
comprehensively investigate the effects of H. pylori on clinically relevant hallmarks of 
food allergy. We found H. pylori to be protective in all four murine models of food 
allergy. Depending on the model, different read-outs were more or less affected by the 
distinct treatments. In the OVA-model, which was the only model applied using 
systemic sensitization and subsequent oral challenge, as well as in the orally peanut-
sensitized and challenged model, the observed anaphylaxis symptoms were very mild 
and therefore mice were challenged and observed repetitively. Consequently, TH2 
cytokines in the supernatant of re-stimulated splenocytes and MCPT-1 levels in blood 
sera were generally lower than measured in other models. In contrast, mice challenged 
intraperitoneally with peanut extract or in case of the C3H mouse strain, we observed 
very strong anaphylactic signs, even after only one i.p. or oral (C3H) challenge. On the 
one hand, this indicates that independent of the sensitization route and allergen used, 
B6 mice clearly react to an oral food challenge, however, the reaction is much more 
evident and stronger upon systemic i.p. challenge, which is not the common natural 
route of food antigen exposure, but still reflects the existence of an allergy against the 
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food injected. On the other hand, these results demonstrate that the C3H mouse strain 
is better suited to elicit strong anaphylactic symptoms as well as MCPT-1 secretion 
upon oral peanut sensitization and challenge. As mentioned in the introduction (1.1.2.4 
Animal models), these differences are influenced by many factors that are not yet fully 
understood. C3H mice might react better to an oral peanut challenge due to a TLR4 
mutation that blocks intestinal LPS signaling. However, this might only be one part of 
the underlying mechanisms since BALB/c mice artificially harboring the same mutation 
still lack responsiveness in such food allergy protocols200,201. Further investigations into 
H. pylori's effects on food allergy induced in C3H mice would certainly be of interest 
due to the model's robustness and stronger responsiveness, albeit, bearing in mind 
that mechanistic insights might be difficult to elucidate because of limited availability of 
genetically manipulated mutant strains. 
4.1.3 Effects of neonatal infection on food allergy 
In previous years, our lab has convincingly shown that neonatal infection of mice with H. 
pylori leads to protection against allergic asthma, by reducing airway inflammation, 
airway hyperresponsiveness and goblet cell metaplasia to almost background 
levels297,321,325. Here, we tested neonatal infection in four different models of food allergy. 
We observed a strong and significant reduction of anaphylaxis-associated symptoms in 
the OVA-model, and to lesser extent in the orally and i.p. challenged peanut-model. No 
alleviation of symptoms was detected in the C3H mouse strain peanut-model (data not 
shown). However, in this model only one experiment was conducted, thus, conclusions 
have to be drawn carefully. Furthermore, in the OVA model, neonatal infection strongly 
reduced systemic parameters such as IL-5 and IL-13 in the supernatant of re-
stimulated splenocytes and OVA-specific IgG1 in the blood whereas other systemic 
readouts like allergen-specific IgE and MCPT-1 in serum exhibited an opposite trend. In 
other models we still observed a minor reduction of MCPT-1 upon infection. However, 
in the systemically induced peanut food allergy model no decline of TH2 cytokine 
secretion from splenocytes and an increase of MCPT-1 upon infection was observed. In 
the C3H peanut model, the latter two parameters were barely changed upon H. pylori 
infection whereas a slight reduction of allergen-specific IgE and the spleen weight 
relative to uninfected mice were measured (data not shown). It is difficult to explain 
these discrepancies between the models and the different read-outs assessed. One 
pattern that can be deduced from these findings is that no decrease or even an 
increase in MCPT-1 sera levels upon infection was observed in models that were either 
systemically sensitized or challenged, but not in models with local oral sensitization and 
challenge. Furthermore, we could not observe an increase of MCPT-1 levels in the 
blood of neonatally infected adult mice that were not subjected to a food allergy 
protocol (data not shown). Hence, neonatal H. pylori infection alone is not able to elicit 
higher MCPT-1 levels and such higher levels seem to be dependent on a systemic 
allergen trigger accompanied by an infection that activates the mast cells to release 
more MCPT-1. Furthermore, the anaphylaxis symptoms seem to be more effectively 
suppressed by H. pylori infection in models that induce less strong and severe 
anaphylaxis. Overall, the beneficial effects of a H. pylori infection on food allergy were 
not as impressive as its impact on allergic asthma outcome. The stronger effects on 
asthma might be due to the so-called gut-lung axis, an emerging principle proposing a 
special connection between the mucosal immune systems of the gut and the lung 
explaining the effects of gastro-intestinal dysbiosis on lung diseases336. 
4.1.4 Effects of neonatal extract treatment on food allergy 
As reported for neonatal infection, our lab recently showed that weekly application of H. 
pylori-derived whole-cell extract starting at around day 6 after birth induces stable 
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protection from asthma in an OVA-induced asthma mouse model337. Thus, we sought 
to elucidate whether extract treatments might also induce protection against food 
allergy. Indeed, we were able to observe preventive effects in four different models of 
food allergy using two different allergens and two distinct mouse strains. In the OVA-, 
the orally challenged peanut-, as well as the C3H-model all assessed read-outs were 
clearly reduced upon oral extract application, strikingly demonstrating the tolerizing 
characteristic of H. pylori-derived extract in food allergy. For the systemically challenged 
peanut model a lack of efficacy in reducing anaphylactic symptoms was observed for 
orally administered extract whereas other assessed hallmarks were still moderately 
alleviated. Engler et al. reported a similar efficacy in asthma protection for i.p. relative to 
orally injected extract337. Consequently, we tested i.p. application of the extract to 
achieve stronger effects able to suppress the severe systemically induced anaphylaxis. 
Using this strategy we observed a clear reduction of anaphylactic symptoms, despite 
not achieving any clear protection in most other read-outs. Systemic extract application 
appeared to induce a pro-inflammatory response in the spleen, probably boosting the 
numbers of T cells subsequently re-stimulated ex vivo and thus, no protection was 
detectable when assessing the levels of splenic IL-5 and IL-13 despite observing 
strongly reduced symptoms. In the same line, it is known that sub-lethal systemic 
endotoxin application may result in splenomegaly338. However, the endotoxicity of H. 
pylori-derived LPS is very low relative to other bacteria261,262,264. To further investigate 
this, one would need to test several dosages of systemic extract application in mice not 
subjected to a food allergy protocol and subsequently look into the quantity of various 
effector cell populations in the spleen. 
4.1.5 Effects of neonatal VacA treatment on food allergy 
Similarly to the above-mentioned H. pylori treatments, the H. pylori-derived 
immunomodulatory protein VacA was proven to be sufficient for preventing allergic 
asthma in an OVA-induced experimental mouse model337. Hence, testing the effects of 
this protein in our food allergy models after observation of protecting effects of live 
infection and extract treatment was an obvious next step. VacA effectively reduced 
anaphylactic symptoms in all of the four models tested (data for OVA model not 
shown), as well as reduced MCPT-1 levels in the blood in most studies. Allergen 
specific-IgE levels were lower in all models except for the orally sensitized and 
challenged B6 peanut model. Also inconsistent results were obtained for the measured 
cytokine concentrations in the supernatant of re-stimulated splenocytes. As shown by 
Engler et al. systemic i.p. application of VacA was sufficient to suppress asthmatic 
hallmarks, and oral application exhibited also protective effects337. The inconsistency of 
VacA's protective effects on food allergy-related read-outs may therefore partially be 
attributed to the application route, which may define the grade of efficacy of VacA by 
making it better or less accessible to the - depending on the allergy protocol - distinctly 
affected tissues and cells. Consequently, elucidating the best application route and 
dosage dependent on the food allergy model used, is the next logical step to confirm 
the effects of VacA treatment on the course of food allergy. 
4.1.6 Tregs play a major role 
In this work we could demonstrate that Tregs increase in quantity but also upregulate 
the expression of FoxP3, IL-10 and TGF-β upon exposure of the mice to H. pylori and 
its products. Similarly, we were here (see below) and previously able to link the 
protection against allergic asthma to the strong suppressive activity of H. pylori-induced 
Tregs. In recent work we have also shown that the induction of Tregs depends on the 
virulence factor VacA. H. pylori strains lacking a functional VacA were not capable of 
colonizing the murine stomach persistently and at wild-type level, and VacA mutants 
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failed to induce suppressive Tregs and to confer protection against asthma. In contrast, 
purified VacA mimicked most of the beneficial effects of a live infection. Interestingly, the 
asthma-protective effect of H. pylori-derived extract seems not to be dependent on 
Tregs, as adoptive transfer of Tregs from neonatally infected mice were able to 
suppress allergic asthma in the recipient mice whereas Tregs from extract treated mice 
were not able to do so297,298,321,337. In line with this finding we also could not observe a 
clear increase of the percentage of Tregs in the mesenteric lymph nodes of extract 
treated mice although VacA treatment and infection clearly increased the frequency of 
these cells. Nevertheless, both, IL-10 and TGF-β expression was elevated upon extract 
treatment, which hints towards the fact that Tregs might play an important role also for 
extract treatment. 
Here, we additionally found an epigenetic correlate of the allergy-preventing activity of 
Tregs from an H. pylori-exposed host. The Treg specific demethylated region (TSDR) of 
Tregs sorted from mesenteric lymph nodes exhibited lower CpG island methylation 
patterns upon neonatal infection, extract and VacA treatment relative to untreated 
control mice. This region essentially controls the stability of FoxP3 expression, hence, 
demethylation enhances stable lineage differentiation and functionality129,131,132. The here 
detected altered epigenetic signature of Tregs derived from H. pylori exposed mice, 
clearly reflects the immunomodulatory effects we observed upon H. pylori infection, 
extract and VacA treatment, that eventually resulted in protection from food allergy, 
previously shown for allergic asthma. Furthermore, the fact that VacA alone is able to 
induce all of the afore-mentioned Treg-associated effects, demonstrates that the strong 
immunomodulatory properties of H. pylori are mediated, at least in part, by the VacA 
protein. 
4.2 H. pylori protects against allergic asthma 
4.2.1 Neonatal extract tolerization requires BATF3, IL-10, IL-18 but not 
Tregs 
We could show (see results, Engler et al.337) that intragastric or intraperitoneal weekly 
administration of H. pylori whole cell extract starting on day 6 after birth efficiently 
prevents allergic asthma development in mice. Thereby, the treatment circumvents the 
carcinogenic properties of a live infection but still harbors the bacteria's beneficial 
tolerogenic effects. Interestingly, the protection was as protective as live infection with 
H. pylori, and was, as reported for the infection321, most effective if started at the 
neonatal age. This differential susceptibility of neonates and adults may be due to the 
immature neonatal immune system harboring higher Treg/Teffector cell ratios and Treg-
prone responses to foreign antigens339. Although our lab could show that the tolerizing 
effects of a neonatal infection on asthma are highly dependent on H. pylori-induced 
Tregs297,321, extract treatment-dependent protection seems to be rather independent of 
this cell type. Adoptive transfer of Tregs from neonatally infected mice to naive 
recipients protected against asthma in contrast to the same transfer using Tregs from 
extract-treated mice, which was not protective. Furthermore, depletion of CD25+ Tregs 
by applying a depleting antibody against CD25 did not affect the extract-induced 
protection. Accordingly, H. pylori extract treatment, in contrast to live infection, of bone 
marrow derived DCs failed to promote the expression of FoxP3 in cocultured naive T 
cells, which suggests a Treg-independent mechanism for tolerance induction in case of 
extract treatment. Indeed our lab could show in earlier research that H. pylori-specific 
tolerance is a consequence of tolerogenic reprogramming of DCs by the bacteria. Here, 
Engler et al. could demonstrate that preferentially CD103+CD11b- DCs were recruited to 
protected lungs and that protection was dependent on this population. Mice lacking the 
transcription factor BATF3, which drives the development of CD8α+ lymphoid tissue-
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resident DC lineages and of the closely related CD103+CD11b- DC lineages in various 
tissues including the lung, intestine and skin, were not responsive to protection 
conferred by H. pylori extract application or live infection337. We further could 
demonstrate that lymph node derived DCs from mice lacking BATF3 are unable to 
produce IL-10 upon exposure to H. pylori extract ex vivo whereas wild-type bone 
marrow or lymph node derived DCs secrete IL-10 upon extract treatment dependent on 
TLR2 and the downstream adaptor protein Myd88337. Additionally, blockade of IL-10 
signaling by means of an anti-IL-10R antibody abrogated the protection against asthma 
and transgenic CD11c-Cre-IL-10fl/fl mice lacking IL-10 specifically in all CD11c-
expressing cells exhibit diminished protection. Thus, IL-10 is crucial for extract induced 
asthma protection and the major source of this cytokine in this context seems to be 
CD11c-expressing cells, which is further confirmed by the fact that IL-10 secretion by 
ovalbumin-restimulated CD11c-Cre-IL-10fl/fl total lung cells is diminished by half relative 
to the wild-type counterpart. 
Oertli et al. have shown that DC-derived IL-18 is important for Treg induction and that 
H. pylori-infected IL18-/- and IL18R-/- mice do not benefit from protection against 
asthma297. Although Tregs seem not to play a major role in the extract-conferred 
protection against asthma, Engler et al. show here, that IL18R-/- mice fail to build up a 
protection against asthma upon extract treatment. Thus, IL-18 must play a crucial role 
for extract-mediated tolerance induction beyond the direct involvement of Tregs. 
Recently, our lab could further confirm the importance of IL-18 by elucidating the 
involvement of the TLR2/NLRP3/IL-18 axis in H. pylori-induced asthma protection325. 
We could show that H. pylori's urease B subunit (UreB) initiates the TLR2 dependent 
expression of NLRP3, which leads to the assembly of the NLRP3-inflammasome and 
subsequent production of IL-1β and IL-18 promoting tolerance and protection against 
asthma325,328. 
In conclusion, our lab could show here and previously that H. pylori mediates immune 
tolerance and protection against OVA-induced asthma by induction of IL-10 derived 
from BATF3-dependent DCs and IL-18 via the TLR2/NLRP3 axis. This either promotes 
Tregs or in case of extract treatment may directly influence T effector responses. 
4.2.2 Advantages of the HDM and the OVA models 
As already discussed in the introduction (1.1.1.4 Animal models of allergic asthma), the 
HDM-induced allergic asthma mouse model harbors a few advantages over the OVA-
induced model. Firstly, the HDM model does not require any additional adjuvants 
besides the HDM-extract itself due to its intrinsic immunogenic properties probably 
attributed to 19 epitopes340 and to the house dust mite's own microbiota containing 
many bacterial and fungal products such as LPS and β-glucan161-165, whereas the OVA-
model usually relies on an adjuvant like aluminum hydroxide. Secondly, HDMs are the 
main allergens responsible for allergic asthma in humans, which endows the model with 
more translatability relative to the OVA allergen, which is not known to cause asthma in 
humans. Furthermore, the OVA model used here and previously in our lab, consists of 
two sensitizations with a gap of two weeks in-between, another two weeks later, 
challenge on three consecutive days is started before mice are sacrificed. In contrast, 
the HDM model employed here, consists of only one intranasal sensitization, and eight 
days later mice are subjected to five challenges before the endpoint on day 15, which 
renders the model much shorter than the OVA model. 
Using the HDM model we observed here and for other projects a more robust positive 
to negative control ratio relative to the OVA model. Moreover, eosinophilia was more 
pronounced in the HDM model resulting in 105-106 eosinophils counted per mL BALF 
whereas in the OVA model only 104-105 were measured on average. Interestingly, in our 
hands, lung inflammation and goblet cell metaplasia seems to be comparable between 
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the two models325,337. Regarding the protection against asthma conferred by H. pylori, 
Koch et al. could show that a neonatal infection induces significantly lower eosinophilic 
lung infiltration, lung inflammation, goblet cell metaplasia and HDM-IgE serum levels, 
and thus, is protective also in the HDM model as previously shown for the OVA 
model325. Likewise, we demonstrate here, that neonatal extract and VacA administration 
diminishes all assessed hallmarks of asthma in the HDM model to a similar extent as 
observed in the OVA model although mice are slightly less protected, probably due to 
the generally higher severity generated by the HDM model. One drawback of the HDM 
model was the fact that our lab was not able to measure elevated IL-5 secretion from 
lung single cell preparations upon re-stimulation with HDM, and base line IL-5 secretion 
was increased in contrast to the OVA model. The larger number of eosinophils or the 
presence of innate lymphoid 2 cells (ILC2s), which both secrete IL-5 independently of 
the presence of an antigen, might be responsible for this discrepancy341,342. However, 
we were able to establish further read-outs in the HDM asthma model, such as the 
assessment of HDM-specific IgE in blood serum and of the IL-13 protein concentration 
in lung homogenates. To further extend the model, recently published protocols for re-
stimulation of mediastinal lymph node single cell preparations and flow cytometric 
analysis of these cells might be worth establishing, to more accurately evaluate the T 
cell response156. Furthermore, intratracheal instead of intranasal sensitization might 
lower the variability of the HDM model. 
4.2.3 Transmaternal exposure to H. pylori prevents asthma development 
in progeny 
4.2.3.1 Transmaternal extract and VacA exposure is highly protective 
Early life acquisition of H. pylori has been shown to be protective against allergic 
asthma in several epidemiological and experimental studies, especially in children and 
young adults or mice infected during the so called neonatal window of 
opportunity51,297,313,321,325. Furthermore, as discussed above, experimental murine 
models could extensively show that neonatal exposure to H. pylori derived extract or 
purified VacA confers protection against allergic asthma and food allergy337. Here we 
set out to extend these findings by exploiting the effects of prenatal exposure to H. 
pylori during pregnancy, transmaternal postnatal exposure during lactation or the 
combination of both. To omit the risk of vertical transmission of the infection from dam 
to offspring, which is deemed to be one of the major routes of H. pylori transmission in 
humans322, we instead focused on treatments with H. pylori extract and VacA. We 
found that oral extract treatment during pregnancy and lactation significantly reduced all 
assessed hallmarks of allergic asthma in the offspring, irrespective whether the pups 
were exposed only pre-, only postnatally, or both. These effects were mimicked when 
the offspring was exposed pre- and postnatally to oral VacA treated or to 
intraperitoneally postnatally VacA treated mothers. Strikingly, the degree of protection 
was comparable to direct neonatal treatment with either extract or VacA. 
In contrast to the concept of direct probiotic treatment and exposure to a diversified 
microbiota embracing many scientific reports and clinical studies, such transmaternal 
(exclusively via the mother) asthma-protective effects have not yet extensively been 
tested in experimental models. However, in line with our findings here, it has been 
postulated that early life and, probably more effectively, prenatal exposure to certain 
microbes is particularly protective against allergic diseases. In humans, children of 
mothers exposed to farming environments during pregnancy had a lower risk for allergy 
development24,25. Additionally, Conrad et al. could demonstrate that maternal prenatal 
intranasal exposure to the nonpathogenic cowshed-derived bacterium Acinetobacter 
lwoffii F78 protects against the development of experimental asthma in the progeny343. 
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Moreover, clinical studies have shown that prenatal supplementation of the mother with 
Lactobacillus and Bifidobacterium prevents sensitization to common food allergens and 
reduces the incidence of atopic eczema in early childhood4. Systematic reviews and 
meta-analyses propose that a combination of pre- and postnatal probiotic 
supplementation is most efficacious in preventing the development of infant eczema 
and atopic eczema344-347, yet no convincing data on beneficial effects on later-onset 
immunological disorders such as wheezing or allergic asthma have been reported to 
date348-351. This lack of efficacy might be partly attributable to the time point of treatment 
start, which is often late in the last trimester of pregnancy or postnatally352. Increased 
efficacy has been found for initiating the intervention at the beginning of the second 
trimester353. 
Since we observed similar protection for pre- and postnatal exposure, we suggest that 
protective factors are transmitted or induced via placental blood exchange and/or the 
milk in case of postnatally-induced protection. By transiently colonizing germ-free 
pregnant mice Ganal-Vonarburg et al. could recently show that the offspring's immune 
system is affected depending on transmission of maternal antibodies that retain 
microbial molecules during pregnancy and in milk354. The underlying mechanisms of in 
utero and postnatal transmission of H. pylori-mediated protection might be related or 
completely distinct; this remains to be elucidated. 
Interestingly, extract derived from an E. coli strain did not induce protection against 
asthma in our experiments, indicating that we observed H. pylori-specific and not purely 
endotoxin/LPS-dependent effects and that probably only strong immunomodulators like 
H. pylori are able to mediate postnatal allergy prevention. 
Although we observed strong and consistent dampening of eosinophilic infiltration, 
goblet cell metaplasia and lung inflammation upon transmaternal H. pylori extract or 
VacA treatment, we measured rather inconsistent and unstable effects on HDM-specific 
IgE in the blood serum and IL-13 in lung homogenates. This might originate from the 
inability of transmaternal H. pylori exposure to reduce initial sensitization towards an 
allergen, hence IgE levels are only slightly decreased or it might be caused by technical 
issues of the self-made, yet not fully optimized ELISA used to assess the allergen-
specific IgE levels. In case of IL-13, one could try to re-stimulate lung or mediastinal 
lymph node cells ex vivo to achieve more consistent results in the future. 
Hypothesizing that the progeny of extract treated dams might be generally 
immunosuppressed, in particular in the lungs considering the significant protection from 
allergic airway disease, we tested their ability to handle a pulmonary influenza A virus 
infection. To our surprise, the viral infection broke the tolerance and the treated mice 
seemed not to be impaired in mounting an anti-viral response, clearing the infection and 
recovering from it. 
4.2.3.2 Maternal infection does not protect the offspring against asthma 
Although it seemed to be highly likely that infected dams transmit their infection to the 
offspring making our model not differentiable from a neonatal infection, we tested 
different infection modalities of the maternal animal. To our surprise, we could not 
detect H. pylori in adult offspring, indicating that in mice H. pylori is rather unlikely to be 
vertically transferred from mother to progeny. However, neither neonatal infection nor 
adult infection of maternal animals was able to induce robust asthma-protection in the 
offspring. Out of four studies we observed only once lower hallmarks of asthma upon 
maternal neonatal infection but not adult infection, opposing three other studies for 
which no effects could be observed. This inconsistency might have been arisen due to 
a laboratory animal facility room change after the first study, thus, provoking a slight 
microbiota change of the mice used in later studies and overriding the initially observed 
phenotype. Assuming that the extract- and VacA-associated protection is caused by a 
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direct transmission of these bacterial factors via the placenta or the milk, one could also 
argue that an infection does not provide a sufficient systemic concentration of such 
factors in order to reach and modulate the offspring's immune system. This issue 
certainly deserves further investigations confirming the non-protective effect of a 
maternal infection and elucidating the transmaternal protective mechanism. 
4.2.3.3 Transmaternal exposure to H. pylori extract skews lung T-cell 
responses towards regulatory T-cells required for asthma protection 
By applying multicolor flow cytometry of steady state lung and mesenteric lymph node 
cells harvested from adult mice originating from either extract-treated or mock-treated 
mothers, we analyzed the T cell and myeloid compartments to identify immune 
correlates responsible for the differential susceptibility to HDM-induced allergic asthma. 
In the lungs we found lower frequencies of bulk CD3+CD4+ T cells and TH1 and TH17 
effector cells, whereas certain Treg subsets exhibited an increased frequency. FoxP3+ 
Tregs in general were not altered significantly upon perinatal H. pylori extract exposure. 
In line with these findings, CD103+CD11b- DCs were more frequent, which might be the 
cause of the local expansion of Tregs over T effector cells. CD103+ DCs are known to 
be dependent on the transcription factor BATF3 and for their potency at promoting 
CD8+ T cell immunity as well as Treg differentiation through the production of retinoic 
acid and TGFβ355-358. Engler et al. could also show that these DCs are crucial for H. 
pylori-mediated immune tolerance. BATF3-/- mice do not benefit from extract-, VacA-, 
or infection-induced protection against allergic airway inflammation337. We conducted 
two pilot studies to investigate the dependence of transmaternally-induced protection 
on BATF3-dependent lineages (data not shown) on the parental side. In one study, 
offspring from treated BATF3-/- mothers bred with wild-type males had an abrogated 
protection against asthma compared to offspring from treated wild-type mothers bred 
with BATF3-/- males, clearly indicating a role for BATF3-dependent lineages on the 
maternal side for inducing the protection in the offspring. However, in the second pilot 
study this trend could not be reproduced. Hence, which of the various Treg subsets is 
primed by CD103+ DCs, and whether transmaternal H. pylori-mediated protection 
requires these DCs remains to be determined. 
Three Treg subsets were over-represented in the lungs of transmaternally-exposed 
animals: Nrp1-, so-called iTregs or pTregs, most probably induced in the periphery in a 
thymus-independent manner, RORγt+ and CXCR3+ Tregs (consisting of p- and to a 
lesser extent of tTregs). The TH1 effector T cell master transcription factor T-bet drives 
the expression of the chemokine receptor CXCR3, which in turn can be used as a 
marker for cells that at some stage of their ontogeny expressed T-bet359. RORγt is 
known to be the master transcription factor for TH17 effector CD4+ T cells109. 
Paradoxically, it became recently apparent that certain activated Tregs express the 
aforementioned effector CD4+ T cell transcription factors which probably endows them 
with enhanced suppressive capacity. Elimination of T-bet expressing Tregs, but not T-
bet expression in Tregs, leads to severe TH1-driven autoimmunity. Furthermore, T-bet+ 
Tregs quite stably express T-bet and were shown to specifically co-localize with TH1 
effector T cells, inhibiting CD8 and TH1 T cell activation359. These results demonstrate 
that Tregs' functional heterogeneity is crucial for immunological tolerance and goes in 
line with our findings of H. pylori-induced CXCR+ (T-bet-dependent) Tregs. Our results 
indicate that despite probably being induced and recruited by specific T effector 
responses, these specialized Tregs are also able to suppress other immune responses 
than their specialization would let assume, as already proposed by Gérard Eberl109. In 
our experiments TH1- and TH17-Tregs are expanded and might suppress a TH2 
mediated response besides dampening TH1 and TH2 immunity characterized by the 
decreased frequency of IFNγ+ and IL-17+ T cells. Counter-intuitively, TH2 specific IRF4+ 
DISCUSSION 
 
 119 
Tregs (probably regulated by the master transcription factor GATA3)134 are rather 
decreased upon transmaternal H. pylori exposure. This most probably is caused by the 
aforementioned expansion of TH1 and TH17 Tregs at the expense of TH2 Tregs 
according to the principle of immunity by equilibrium109. 
Interestingly, in the mesenteric lymph nodes (MLN) we could not entirely reproduce the 
immunophenotype observed for the lungs. However, we observed similar to the lungs a 
decrease of migratory DCs and a higher CD103+/CD11b+ ratio, indicating skewing 
towards a regulatory over an effector response. The lack of a shift of TH1, TH17 or TH2 
Tregs in the mesenteric lymph node as well as in the spleen (data not shown) might be 
attributable to the assumption that these specialized Tregs are induced and fully 
differentiated or expanded peripherally in target organs/tissues, which in case of H. 
pylori might be mainly the lungs, probably due to the putative existence of a strong gut-
lung axis336. 
Supporting the important role Tregs play in transmaternally tolerized mice, we could 
demonstrate here, that the systemic ablation of FoxP3+ Tregs just before and during the 
challenge-phase of the asthma-protocol abolishes H. pylori-mediated transmaternally-
induced protection. Obviously, the mucus-secreting goblet cell infiltration and the lung 
inflammation score, as well as other hallmarks were aggravated by the systemic 
depletion of Tregs, which leads to a distortion of the observed effect. Thus, it would be 
highly interesting to specifically deplete only TH1 or TH17 Tregs, to terminally confirm 
their importance in our observed phenotype. However, this would first require the 
design and generation of suitable mutant mouse strains. One initial approach might also 
be to cross the RORγt-flox mouse with the FoxP3-cre mouse (both available from the 
Jackson Laboratory), to specifically ablate RORγt expression in Tregs. 
4.2.3.4 Transmaternal exposure to H. pylori extract or VacA affects the diversity 
and composition of gastrointestinal bacterial community structures 
To elucidate whether perinatal extract or VacA treatment also alters the gastrointestinal 
microbiome in addition to altering allergy severity and immunological correlates of 
protection, we conducted a 16S rRNA sequencing of samples harvested from the 
stomach, ileum, cecum and colon. Beta-diversity analysis showed that samples are 
clearly segregated by treatment and evidently by anatomical site. Furthermore, for each 
site, samples significantly agglomerated by the respective maternal treatment (PBS, 
extract or VacA), this was most pronounced in the stomach and ileum. Linear 
discriminant analysis effect size revealed that different treatments induce higher or lower 
abundance of different taxa. In conclusion, maternal exposure to H. pylori 
immunomodulators during pregnancy affects gastrointestinal bacterial community 
structure much later in the adult progeny. This is most probably a consequence of 
skewing of steady state immune parameters towards a tolerogenic phenotype (as 
described above), and not the cause of it, because cecal microbiota transplantation 
from transmaternally protected adult mice to naive newborns was not sufficient to 
protect against asthma. However, this preliminary piece of data has to be confirmed by 
further transplantation or co-housing experiments. 
Interestingly, certain taxa that were more or less abundant upon treatment are 
associated with healthy or diseased states. Perinatal VacA treatment led to the 
enrichment of Ruminococcaceae Clostridium in the stomach, which belong to the 
Clostridium cluster IV, and notably, atopic patients have been shown to possess lower 
levels of cluster IV Clostridium species360. Moreover, in the ileum perinatal VacA 
treatment resulted in the depletion of Clostridiaceae Candidatus Arthromitus belonging 
to the group of segmented filamentous bacteria associated with a high TH17 
response361-364. Recently, Kim et al. showed that colonization of pregnant mice with 
segmented filamentous bacteria increases the risk for neurodevelopmental disorders in 
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the offspring365, underlining how changes of these gastrointestinal communities may 
have far-reaching consequences. 
4.2.3.5 Transmaternal extract and VacA treatment induce demethylation of the 
Treg-specific demethylated region (TSDR) in FoxP3+ Tregs 
As previously mentioned, the cowshed-derived bacterium Acinetobacter lwoffii F78 
induces transmaternal asthma protection as observed for H. pylori modulators 
described here343. The effects of Acinetobacter lwoffii F78 were dependent on TLR 
signaling, IL-6, IL-12 and TNFα production in the mother and epigenetically influenced 
IFNγ production in the offspring, by protecting CD4+ T cells against loss of the activating 
histone 4 acetylation in the promoter region of IFNG upon OVA sensitization. In 
contrast, reduced histone 4 acetylation was observed at the IL4 promoter366. However, 
they did not observe any changes of the methylation pattern at these promoters. These 
results indicate that in pregnancy such environmental-stimuli are able to quickly induce 
long-lasting epigenetic changes. In our experiments transmaternal H. pylori exposure 
changed the methylation pattern of Tregs within the so-called Treg-specific 
demethylated region (TSDR). The TSDR is localized within an intronic enhancer region 
of the X-chromosome-linked Foxp3 locus and is selectively demethylated in lineage-
committed, stable Tregs367,368. Analysis of sorted MLN-derived Tregs of offspring from 
extract, VacA or sham treated mothers revealed a demethylation of all analyzed CpG 
islands within the TSDR upon different H. pylori treatments, indicating that on average 
Tregs are more stable. Although, in a preliminary experiment we could not detect 
methylation changes at the IFNG promoter, other regions might be differentially 
methylated upon transmaternal treatment and also histone modification marks might be 
altered. Further studies are needed to elucidate these putative changes at other tissue 
sites, which is difficult to assess since more than 3x105 male cells are required for a 
comprehensive TSDR methylation analysis, which so far has restricted our efforts to 
lymph nodes. Furthermore, analysis of CD4+FoxP3- T cells as conducted for the 
Acinetobacter-study would also be of interest. Currently, our lab is working on 
establishing the assay for transposase-accessible chromatin using sequencing (ATAC-
seq), a technique able to reveal chromatin accessibility on a whole-genome scale using 
as little as 50'000 cells. Using this assay would allow us to identify and have a closer 
look at all regions which are epigenetically altered, hence chromatin changes are 
induced, upon transmaternal H. pylori exposure. By applying quantitative real time PCR, 
we could also show that H. pylori-specific perinatal treatment induces a modestly 
higher expression level of TGFβ but not FoxP3 or IL-10 in Tregs sorted from lungs and 
MLN, further confirming the treatment's impact on Treg quality and not only quantity of 
certain subsets. Collectively, we conclude that the epigenetic marks leading to stable 
expression of FoxP3 and potentially to Treg-specific transcript changes, reflect the 
suppressive effects of transmaternal H. pylori treatments on allergic asthma.  
4.2.3.6 The decreased susceptibility to allergic asthma by exposure to H. pylori 
extract is intergenerationally transmitted to the F2 generation 
The most remarkable discovery we made in the course of our studies was that H. 
pylori-dependent transmaternal protection against experimentally-induced allergic 
asthma is intergenerationally transmitted to the F2 generation. Our experiments do not 
rule out the possibility that H. pylori extract directly influences the gametes (that later will 
give rise to the F2 generation) of the developing fetus (F1) in utero. In line with that, it 
was shown that the risk for allergy and asthma inherited from the mother is up to 5 fold 
higher than the paternal risk, which partly might be explained by parental imprinting or 
by direct modification of the fetal immune system in utero369-372. Our lab is currently 
setting up such breedings, to disclose whether the observed effects are only 
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transmitted intergenerationally or even transgenerationally to the F3 generation. 
Interestingly, for crossings that gave rise to the F2 generation, it did not matter for 
asthma-protection in the F2 offspring, whether only the male, only the female or both 
originated from a dam that was treated during pregnancy, ruling out any Mendel-like 
inheritance of asthma-protection (considering that the protection might be linked to the 
X-chromosome linked Foxp3 locus). Our findings so far, strikingly demonstrate how 
microbial exposures strongly affect allergy risk even across multiple generations. 
Similar observations were made for tobacco smoke exposure. Pooled analyses from 15 
European birth cohorts demonstrated that even exposure of the mother (non-smoking) 
to only second hand smoke during the pregnancy will lead to an increased risk for 
wheezing at age 2 years, which is further increased by postnatal second hand smoke 
exposure and further elevated in children of atopic families103. Most strikingly, Li et al. 
could show that not only maternal but also grand maternal smoking during the mother's 
fetal period may increase the risk for childhood asthma104. Furthermore, in a nicotine-
induced asthma model in rats, Rehan and colleagues could demonstrate that asthma 
provoked by nicotine exposure is transgenerationally transmitted to the F3 
generation373. Additionally, the pace of the development of the allergic epidemic cannot 
solely be explained by genetic factors, and further hints towards the involvement of 
environmentally induced epigenetic mechanisms influencing several generations. 
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5 Concluding remarks 
A plethora of epidemiological, clinical and experimental data impressively demonstrates 
the vast influence of environmental factors ("exposome") on allergy susceptibility. Most 
of these factors either directly or indirectly shape the gastrointestinal and/or pulmonary 
microbial community structure and microbiome diversity of the affected individual, 
which in turn affects maturation of the immune system and therefore disease 
susceptibility. 
H. pylori co-evolved over thousands of years with its host, which allowed it to adapt to 
the human immune system employing a range of immune evasion and manipulation 
mechanisms. This enables the bacterium to efficiently colonize the gastric mucosa. We 
and others could show that H. pylori is a fundamental part of the exposome, not only 
being a pathogen but also beneficially affecting allergic disease outcome, turning this 
bacterium into a pathobiont (i.e. a symbiont that is able to provoke pathology when 
specific genetic or environmental settings are changed in the host). 
Herein and recently, we could demonstrate in experimental mouse models that 
neonatal infection leads to robust asthma protection in the adult host in a Treg-
dependent manner via the TLR2/NLRP3/IL18 axis. These effects could be mimicked by 
using H. pylori-derived extract and were shown to rely on the immunomodulator VacA. 
Protection against asthma conferred by H. pylori extract was shown to be mediated by 
BATF3-dependent DCs secreting IL-10. Here, we further extended the protective 
effects to a range of experimental food allergy models, showing that neonatal infection, 
extract and VacA treatment prevents, although less efficiently and robustly than in the 
asthma model, food allergy development. We now further demonstrated for the first 
time, the beneficial, also Treg-dependent, impact of prenatal and postnatal 
transmaternal H. pylori exposure on asthma susceptibility in the progeny and 
characterized the associated altered immune correlates such as a decreased frequency 
of DCs and bulk CD4 T cells and increased frequencies of specialized Treg subsets in 
the lungs. Furthermore, these effects were linked to shifts in the microbiota 
composition, as well as the epigenetic signature of Tregs indicating qualitative and/or 
quantitative differences in the stability and functionality of Tregs. Notably, transmaternal 
H. pylori exposure did not lead to a generalized immunosuppression as an acute 
infection with influenza A virus was readily controlled by the mice. These observations 
suggest the suitability of H. pylori-derived products such as VacA as potentially 
preventive drugs against the allergy epidemic, especially if applied early or even 
prenatally in atopic families. Most strikingly, we observed that the asthma-protective 
effects were propagated to the second generation without any further treatments, 
highlighting the importance of a healthy exposome - Of which H. pylori constitutes a key 
player - in shaping allergy risk and severity over several generations. 
Further research is required to elucidate the mechanism and routes responsible for 
tolerance transmission in the first and second generation on the maternal side as well 
as tolerance induction on the offspring side. It would also be of great interest to test the 
existence of, and to shed light on a potential phenotype in the F3 generation. Moreover, 
to identify the genome-wide epigenetic changes involved in the observed phenotype, 
our lab is currently establishing the ATAC sequencing method. Finally, the here 
observed ability of pre- and postnatally supplied H. pylori to skew the developing 
immune system intergenerationally towards immune tolerance, might also apply to 
other constituents of the exposome, thus, opening up many new options for probiotic 
allergy prevention. 
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6 Abbreviations 
Ag    Antigens 
AIT    Allergen immunotherapy 
AP1    Activator protein 1 
APC    Antigen presenting cell 
ASC  Apoptosis-associated speck-like protein containing a CARD 
ATAC-seq Assay for transposase-accessible chromatin using sequencing 
ATF    Activating transcription factor 
ATP    Adenosine triphosphate 
BALF    Bronchoalveolar lavage fluid 
BATF3    Basic leucine zipper ATF-like transcription factor 3 
Cag-PAI   Cag pathogenicity island 
CagA    Cytotoxin-associated gene A 
cAMP    Cyclic adenosine monophosphate 
CCL2    C-C motif chemokine ligand 2 
CCL20    C-C motif chemokine ligand 20 
cDC    Conventional DC 
CDXY    Cluster of differentiation XY 
CED    Chronisch entzündliche Darmerkrankungen 
CLR    C-type lectin receptor 
CNS2    Conserved noncoding sequence 2 
CREB    cAMP-responsive-element-binding protein 
CS    Cesarean section 
CT    Cholera toxin 
CTLA-4   Cytotoxic T-lymphocyte-associated protein 4 
CXCR3   C-X-C motif chemokine receptor 3 
d    Deletion region 
DC    Dendritic cell 
DC-SIGN DC-specific intercellular adhesion molecule-3-grabbing non-integrin 
DNA    Deoxyribonucleic acid 
DTH    Delayed-type hypersensitivity 
EPIT    Epicutaneous immunotherapy 
ETS    Environmental tobacco smoke 
FcγRII I/ IV   IgG Fc γ heavy chain binding receptor III or IV 
FcεRI    IgE Fc ε heavy chain binding receptor I 
FoxP3    Forkhead box P3 
GATA3    GATA binding protein 3 
GGT    Gamma-glutamyl transpeptidase 
GI    Gastrointestinal 
GM-CSF   Granulocyte-macrophage colony-stimulating factor 
GWAS    Genome-wide association studies 
hBD2/3   Human beta-defensin 2 or 3 
HDM    House dust mite 
HLA    Human leukocyte antigen 
HRV    Human rhinovirus 
i    Intermediate region 
i.p.    Intraperitoneal 
IBD    Inflammatory bowel disease 
ICAM-1   Intercellular adhesion molecule 1 
IFN-γ    Interferon-γ 
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IgE/G1/A   Immunoglobulin E, G1 or A 
IL-XY    Interleukin-XY 
IL18R    IL-18 receptor 
ILC    Innate lymphoid cell 
ILC1/2/3   Group 1, 2 or 3 of innate lympoid cells 
iNOS    Inducible nitric oxide synthase 
IRF3    Interferon regulatory factor 3 
IRF4    Interferon regulatory factor 4 
iTreg    Induced regulatory T cell (or peripherally derived pTreg) 
LAG-3    Lymphocyte-activation gene 3 
LPS    Lipopolysaccharide 
m    Mid region 
M cells    Membrane cells 
MAMPs   Microbe-associated molecular patterns 
MCPT-1   Mast cell protease 1 
MLN    Mesenteric lymph nodes 
mSC    Membrane secretory component 
Myd88    Myeloid differentiation primary response 88 
Mφs    Macrophages 
NCDs    Non-communicable diseases 
NFAT    Nuclear factor of activated T cells 
NK    Natural killer cell 
NLRP3    NACHT, LRR and PYD domains-containing protein 3 
Nrp-1    Neuropilin-1 
nTreg    Natural regulatory T cell (or thymus derived tTreg) 
OIT    Oral immunotherapy 
OR    Odds ratio 
OVA    Ovalbumin 
OX40L    OX40 ligand 
PAF    Platelet activating factor 
PAI    Pathogenicity island 
PAMP    Pathogen-associated molecular pattern 
pIgR    Polymeric Ig receptor 
qPCR    Quantitative polymerase chain reaction 
RA    Retinoic acid 
ROR-γt    Retinoic acid receptor-related orphan receptor-γt 
ROS    Reactive oxygen species 
rRNA    Ribosomal ribonucleic acid 
RSV    Respiratory syncytial virus 
s    Signal region 
SEB    Staphylococcal enterotoxin B 
SIgA    Secretory IgA 
SLIT    Sublingual immunotherapy 
SMAD3   Mothers against decapentaplegic homologue 3 
SNPs    Single nucleotide polymorphisms 
STAT5/6   Signal transducer and activator of transcription 5 or 6 
TBK-1    Serine/threonine protein kinase-1 
TCR    T cell receptor 
TFH    T follicular helper cell 
TGF-β    Transforming growth factor-beta1 
TH1    T helper 1 cells 
TH17    T helper 17 cells 
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TH2    T helper 2 cells 
TIEG1    TGFβ -inducible early gene 1 
TLR2/4/9   Toll-like receptor 2/4/9 
TNFα    Tumor necrosis factor α 
TRAP    Traffic-related air pollution 
Treg    Regulatory T cell 
TSDR    Treg-specific demethylated region 
TSLP    Thymic stromal lymphopoietin 
TSLPR    TSLP receptor 
UreB    Urease B subunit 
VacA    Vacuolating cytotoxin A 
VCAM-1   Vascular cell adhesion molecule 1 
WHO    World Health Organisation 
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